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ABSTRACT INTRODUCTION
ABSTRACT
Background- Apoptotic loss of smooth muscle cells (SMCs) and endothelial cells 
(ECs) may cause rupture or erosion of coronary plaques. Infl ammation has been rec-
ognized as one of the key features in the pathogenesis of atherosclerosis, and has been 
suggested to regulate apoptosis in atherosclerotic lesions. Since mast cells form a part 
of the infl ammatory cell infi ltrate in coronary plaques, and are present in increased 
numbers at the vulnerable shoulder regions of human coronary atheromas, the possibil-
ity exists that mast cells may affect the stability of plaques by inducing apoptosis of 
SMCs and ECs.
Methods and Results- By using FACS, TUNEL, immunohistochemistry, and West-
ern blot analysis, we found that chymase released from activated mast cells is able to 
induce apoptosis of SMCs in vitro by a mechanism involving degradation of an ex-
tracellular matrix (ECM) component, fi bronectin (FN), with subsequent disruption of 
focal contacts on the surface of SMCs. Focal adhesion kinase (FAK), one of the key 
mediators of integrin-ECM interactions and cell survival, was rapidly degraded in the 
presence of chymase and/or FN degradation products. Loss of phosphorylated FAK 
(p-FAK) resulted in a rapid dephosporylation of the p-FAK-dependent downstream 
mediator Akt. Furthermore, following chymase treatment, the total amount of NFkap-
paB, a transcription factor critically involved in integrin-mediated SMC survival, was 
reduced and the translocation of active NFkappaB (p65) to the nucleus decreased. Loss 
of NFkappaB-mediated transactivation resulted in downregulation of bcl-2 mRNA 
expression and initiation of apoptosis. Mast cells also induced EC apoptosis by releas-
ing tumor necrosis factor-alpha. The mechanism involves downregulation of bcl-2 and 
release of cytochrome c from mitochondria. Moreover, we demonstrated that mast cell 
chymase inhibits SMC growth and collagen expression.
Conclusions- Our results suggest that chymase and TNF-alpha -secreting mast cells, 
via their secretion products, mediate apoptosis of neighboring SMCs and ECs and thus 
may reduce the stability of coronary plaques.
ABSTRACT
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INTRODUCTION
Atherosclerosis, along with infectious diseases, cancer and mental disor-
ders, is one of the leading global health 
problems. The age-adjusted incidence 
of atherosclerosis in Finland, and the 
Western World in general, has steadily 
declined as effective treatment strategies 
have been developed. However, over 40% 
of deaths in Finland can still be attributed 
to atherosclerosis. This is mainly due to 
a demographic shift towards older popu-
lation. Outside the Western World the 
incidence of atherosclerosis is rapidly in-
creasing, and according to the estimates, 
atherosclerosis will be the leading cause 
of disease burden worldwide by 2020 
(Murray et al. 1996). Our understanding 
of the pathogenesis of atherosclerosis 
has increased. Especially infl ammatory 
mechanisms have emerged as key play-
ers in the formation of atherosclerotic 
plaques, suggesting that atherosclerosis 
is an infl ammatory disease (Ross 1999; 
Libby 2002). The present study focuses 
on one component of the infl ammatory 
system, the mast cell, and its role in the 
pathogenesis of atherosclerosis.
Atherosclerotic lesions develop slowly 
and the early lesions are usually clini-
cally silent for decades. When clinical 
symptoms occur, they are predominantly 
caused either by narrowing of the arter-
ies due to obstructing plaques, or by 
plaque erosion or rupture with subsequent 
local thrombus formation. The former 
mechanism causes stable angina pectoris 
and intermittent claudication. The latter 
causes acute clinical complications, such 
as unstable angina pectoris, myocardial 
infarction, and stroke.
Rupture of the plaque appears to depend 
critically on the thickness of the fi brous 
cap overlaying the lipid-rich core of the 
advanced atherosclerotic plaques (Lee
et al. 1997): a thick cap protects the 
plaque, whereas a thin cap predisposes 
it to rupture and subsequent thrombosis 
INTRODUCTION
Figure 1. Schematic model of an atherosclerotic lesion
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(Falk 1992). The fi brous cap consists of 
arterial smooth muscle cells (SMCs) and 
extracellular matrix (ECM) produced 
and maintained by the SMCs (Lee et 
al. 1997). Thus, it can be surmised, that 
apoptosis of SMCs leading to decreased 
number of SMCs and reduced produc-
tion of ECM could destabilize the plaque 
(Björkerud et al. 1996; Kockx et al.
2000). 
Apoptotic SMCs are present in fi brous 
caps of atherosclerotic lesions (Geng et 
al. 1995; Isner et al. 1995; Kockx et al.
1998), and they often colocalize with 
infi ltrates of infl ammatory cells (Crisby
et al. 1997; Kockx et al. 1998). These 
include macrophages (Björkerud et al.
1996), T-lymphocytes (Björkerud et al.
1996), and mast cells (Kaartinen et al.
1994a; Kovanen et al. 1995). Moreover, 
in acute coronary syndromes, increased 
numbers of activated mast cells can be 
seen in the culprit lesions (Kaartinen et 
al. 1998). These observations raised the 
hypothesis that mast cells could par-
ticipate in the regulation of apoptosis of 
SMCs. 
Plaque erosion without rupture is another 
frequent cause of coronary thrombosis 
(Farb et al. 1996). One of the possible 
mechanisms leading to plaque erosion 
is apoptosis of endothelial cells (ECs) 
(Dimmeler et al. 2002). However, ECs 
in culture are known to be very resist-
ant to apoptosis (Polunovsky et al. 1994; 
Bach et al. 1997), suggesting that special 
pathological conditions are required for the 
induction of excessive EC apoptosis in 
the arterial wall. Recent in vitro studies 
have shown that proinfl ammatory 
cytokines, such as tumor necrosis factor-α 
(TNF-α), can trigger apoptosis of ECs 
(Pohlman et al. 1989; Karsan et al. 1996; 
Wallach 1997). Since mast cells in human 
coronary atheromas produce and store 
TNF-α (Kaartinen et al. 1996), the pos-
sibility exists that mast cells could induce 
apoptosis of ECs and thus contribute to 
the erosion of the coronary plaques. 
In the present study, we provide informa-
tion on mast cell-induced apoptosis of 
SMCs and ECs in vitro and the mecha-
nisms involved. 
INTRODUCTION
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Atherosclerosis
Atherosclerosis is a slowly progress-ing disease characterized by the 
accumulation of cells, lipids and fi brous 
elements in the innermost layer of the 
arterial wall, the intima, in large and 
medium-sized arteries (Stary et al. 1994). 
Atherosclerotic lesions evolve over the 
time from the initial, clinically silent 
fatty streaks into more complex lesions, 
resulting in clinical manifestations of the 
disease, such as angina pectoris, unstable 
angina, myocardial infarction, sudden 
cardiac death and stroke. The pathophysi-
ology of atherosclerosis is a complex 
process involving dyslipidemia, endo-
thelial dysfunction, and infl ammation. 
The role of hypercholesterolemia (Ross
et al. 1976) and endothelial dysfunction 
(Harker et al. 1981) is well established 
and is supported by strong experimental 
and clinical evidence, whereas the im-
portance of infl ammatory mechanisms in 
the pathophysiology of atherosclerosis 
has been understood only recently (Ross 
1999; Libby 2002; Fan et al. 2003). In ad-
dition, several other factors, such as cir-
culating smooth muscle progenitor cells 
(Saiura et al. 2001), infection (Saikku 
2000) and homocysteine (Cook et al.
2002) have been suggested to contribute 
to atherosclerosis.
Early lesions
When plasma low density lipoprotein 
particles (LDL) are present in excess 
quantities, they can undergo modifi ca-
tions, such as oxidation, and accumulate 
in the intima of the arterial wall (Witztum
et al. 1991). This, in turn can provoke 
an infl ammatory response by inducing 
expression of mononuclear leukocyte 
adhesion molecules, such as VCAM-
1, on the surface of ECs (Cybulsky
et al. 1991; Li et al. 1993a; Berliner
et al. 1995; Pentikäinen et al. 2000). 
Moreover, oxidized LDL can initiate 
monocyte migration into the intima by 
inducing production of monocyte chem-
otactic protein-1 (MCP-1) (Cushing et 
al. 1990). In the intima, monocytes dif-
ferentiate into macrophages and begin 
to internalize modifi ed LDL, thereby 
leading to the formation of macrophage 
foam cells. Subendothelial accumula-
tion of such lipid-laden macrophages is 
called a fatty streak and constitutes the 
fi rst visible sign of an ongoing process 
of atherosclerosis (Munro et al. 1988).
The current classifi cation of atheroscle-
rotic lesions, as presented by the Ameri-
can Heart Association, divides the le-
sions into six types based on their histo-
logical composition and structure (Stary
et al. 1994; Stary et al. 1995). Initial 
intimal lesions with isolated groups of 
lipid-laden macrophages in the intima 
are defi ned as type I lesions. Accumu-
lation of large numbers of lipid-laden 
macrophages as layers together with 
lipid-fi lled smooth muscle cells (SMCs) 
are classifi ed as type II lesions (Stary
et al. 1994). Type I lesions may occur 
already in human fetal aortas (Napoli et 
al. 1997), and type II lesions are present 
in the arteries of most children around 
puberty (Stary 2000), indicating the 
very early start of the atherosclerotic 
process. Early lesions are precursors of 
more advanced lesions, however, they 
never obstruct the arterial lumen or dis-
rupt the intimal structure, and therefore 
are clinically silent (McGill, Jr. 1968).
REVIEW OF THE LITERATURE
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Advanced lesions
Early lesions may undergo transformation 
into type III intermediate lesions, which 
contain small pools of intimal extracel-
lular lipid, but no confl uent lipid core. 
Confl uence of these small lipid pools 
to form large lipid core is the fi rst sign 
of clinically signifi cant atherosclerotic 
lesions, defi ned as type IV lesions (Stary
et al. 1995). The large lipid core of these 
lesions causes severe intimal disorganiza-
tion, and may narrow the arterial lumen 
(Stary et al. 1995). Type IV lesions have 
no signs of fi brosis. It is the development 
of a fi brous cap, covering the lipid core, 
which distinguishes the type V lesions, 
i.e., the fi broatheroma, from the type IV 
lesions. Although the formation of the 
fi brous cap is an adaptive response, which 
protects the lesion from rupture, it tends 
to narrow the artery more than type IV 
lesions. 
Complicated lesions
The most important mechanism of mor-
bidity and mortality in atherosclerosis is 
the erosion or rupture of the atheroscle-
rotic plaque, with ensuing thrombotic 
occlusion of the artery (Fuster et al. 1992; 
Falk 1992; Virmani et al. 2000). In autopsy 
studies of human coronary arteries, in 
75% of cases the thrombi had formed at 
the site of a deep intimal tear, extending 
into the center of an atheromatous plaque. 
In 25% of cases thrombi formation was 
associated with superfi cial erosion of the 
fi brous cap (Davies 1990). Such disrup-
tion of the luminal surface may occur in 
both type IV and V lesions (Stary et al.
1995), resulting in the formation of the 
complicated type VI lesions.
Plaque rupture 
The risk of plaque rupture appears to 
depend on plaque composition, circum-
ferential wall stress, and characteristics of 
the blood fl ow (Falk 1992; Fuster 1994). 
The soft lipid core is unable to bear the 
mechanical forces from the blood fl ow, 
and the load concentrates on the fi brous 
cap and especially on its margin, the 
shoulder area. Rupture of plaque occurs 
when stress exceeds the critical level that 
the cap can withstand (Lee et al. 1997). 
Upon rupture, the highly thrombogenic 
lipid-rich core is exposed to circulating 
coagulative proteins leading to formation 
of a thrombus, and to clinical compli-
cations of atherosclerosis. However, if 
spontaneous fi brinolysis is active, the 
thrombus will remain non-occlusive and 
become part of the plaque. Even under such 
favorable conditions the repair process 
leads to plaque growth (Lee et al. 1997).
Interstitial collagen produced by SMCs 
confers most of the tensile strength on 
the fi brous cap (Lee et al. 1997), and is 
thus critical for the stability of a plaque. 
Typically, a stable plaque has a small 
lipid core and a thick fi brous cap, which 
is rich in SMCs and collagen, but poor in 
infl ammatory cells. In contrast, a lesion 
with a large lipid core and a thin fi brous 
cap, containing only few SMCs and little 
collagen, but many infl ammatory cells, is 
prone to rupture (Richardson et al. 1989). 
Infl ammation is considered to occupy a 
central position in the rupture of 
atherosclerotic plaques (Libby 2002). 
The number of infl ammatory cells, such 
as macrophages, T-lymphocytes, and mast 
cells, is increased at the sites of plaque 
rupture, and they destabilize the plaque 
by different mechanisms (Moreno et al.
1994; van der Wal et al. 1994; Kovanen
et al. 1995). For instance, infl ammatory 
cells are the most important source of 
matrix metalloproteinases (MMPs), that 
play a prominent role in the degradation 
of the ECM (Galis et al. 1994; Lijnen 
REVIEW OF THE LITERATURE
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2002). Moreover, cytokines, such as 
interferon-γ, released from T-lymphocytes 
can inhibit the production of collagen by 
SMC (Amento et al. 1991), and can also 
induce their apoptosis (Geng et al. 1998; 
Niemann-Jonsson et al. 2001).
Plaque erosion
Superfi cial plaque erosion without rup-
ture is another frequent cause of coronary 
thrombosis (Farb et al. 1996; Arbustini et 
al. 1999). The exact mechanisms leading 
to plaque erosion have remained enig-
matic, but ECs are thought to have a criti-
cal role in it. The EC monolayer forms 
a barrier between circulating blood and 
the vascular wall, and plays an essential 
role in the physiology of the vessel. Thus, 
a healthy endothelium tends to prevent 
thrombosis, infl ammation, and spasm of 
the artery (Anderson 2003). Factors dis-
turbing the integrity of endothelium, such 
as apoptosis of ECs, increase the risk 
of plaque erosion, exposing the highly 
thrombogenic ECM and causing throm-
bosis (Dimmeler et al. 1998; Dimmeler
et al. 2002). Many of the classical risk 
factors of atherosclerosis, such as smok-
ing (Wang et al. 2001), oxidized lipids 
(Dimmeler et al. 1997), and hyperglyc-
emia (Ho et al. 2000) have been shown to 
be associated with EC apoptosis.
Mast cells 
Mast cells were fi rst characterized in the 
late 19th century by Paul Ehrlich, who 
observed cells with metachromically 
staining granules in connective tissue 
stained with an aniline dye. Ehrlich 
believed that the granules resulted from 
overfeeding of cells, and named the cells 
after the German word Mästung, to mas-
ticate or to feed (Ehrlich 1879). His ideas 
regarding granule origin soon proved 
wrong, but the somewhat misleading 
name remained. Ehrlich also described 
the localization of mast cells in associa-
tion with blood vessels, infl amed tissues, 
nerves, and neoplastic tissues, and pro-
vided the fi rst description of their de-
granulation. Mast cells have been shown 
to participate in various physiological and 
pathological processes, notably in allergic 
reactions (Williams et al. 2000), and also 
in the defense against parasites and bac-
teria (Wedemeyer et al. 2000), in gastric 
acid secretion (Metcalfe et al. 1981), in 
lipoprotein metabolism (Kovanen 1995), 
and in autoimmune diseases (Benoist et 
al. 2002).
Origin of mast cells and their 
differentiation
Mast cells are derived from multipotential 
hematopoietic stem cells originating in 
bone marrow (Rodewald et al. 1996; Li
et al. 1999). Thus, undifferentiated mast 
cell progenitor cells leave the bone mar-
row and circulate in blood and lymphatic 
system before migrating to target tissues, 
notably to various mucosal surfaces and 
to skin, as well as to the arterial wall, 
where they proliferate and differenti-
ate into granulated, mature mast cells 
(Wasserman 1990). Their migration and 
differentiation is infl uenced by several 
cytokines, such as interleukins -3, -4, -9, 
and the nerve growth factor (Madden et 
al. 1991; Mekori et al. 2000). However, 
the most important factor appears to 
be the stem cell factor (SCF), which is 
secreted locally by stromal cells, such as 
fi broblasts (Galli et al. 1993). The critical 
role of SCF is supported by the fi nding 
that SCF-defi cient (S1/S1d) and SCF-re-
ceptor c-kit defi cient (W/Wv) mutant mice 
are largely devoid of mature mast cells 
(Kitamura et al. 1978; Kitamura et al.
1979). Moreover, SCF is the only cy-
tokine that promotes the development of 
16
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mast cells in adult human system (Valent
et al. 1992; Li et al. 1999).
Distribution and heterogeneity of 
mast cells 
Almost all major organs and tissues of 
the body harbor mast cells. Most preva-
lent they are at the interface of the host 
and environment, refl ecting their role in 
primary defense as the “sentinel cells”. 
Thus, mast cells are often found in the 
proximity of blood and lymph vessels, in 
the skin, and in the mucosa of the up-
per and lower respiratory tracts and the 
gastrointestinal tract (Irani et al. 1986; 
Kitamura 1989; Galli 1990).
Mast cell populations are heterogeneous.  
Two major phenotypes, mucosal and con-
nective tissue phenotype, have been iden-
tifi ed in rodent tissues (Irani et al. 1986). 
Mucosal phenotype is predominant in 
the small bowel mucosa and connective 
tissue phenotype in the skin and on the 
serosal surfaces. These phenotypes differ 
in their morphological, histochemical 
and functional properties. For instance, 
heparin proteoglycans (PGs) appear only 
in connective tissue mast cells, whereas 
chondroitin sulphate PGs are found in 
both types of mast cells. The composi-
tion of neutral proteases in the secretory 
granules is also different, rat connective 
tissue mast cells contain chymase I and 
carboxypeptidase A, whereas rat mucosal 
mast cells contain tryptase-like chymase 
II (Kitamura 1989). The local microen-
vironment is able to regulate the mast 
cell phenotype (Austen et al. 2001). For 
instance, mouse mucosal-type mast cells, 
when cultured on fi broblasts adopt certain 
phenotypic characteristics of connective 
tissue type cells (Galli 1990).
Also human mast cells are heterogene-
ous. Two phenotypes have been identifi ed 
based on the protease content: mast cells 
containing both tryptase and chymase 
belong to TC-type (MC
TC
), whereas mast 
cells that contain only tryptase as their 
neutral protease belong to T-type (MC
T
)
(Wasserman 1990). MC
TC 
are the pre-
dominant type around blood vessels (Irani
et al. 1986), and they are analogous with 
rodent connective tissue type mast cells. 
Mast cell stimulation and 
degranulation
The most prominent funtional feature of 
mast cells is their ability, upon activation, to 
exocytose preformed mediators, such as 
the neutral proteases chymase and tryp-
tase, heparin PGs and histamine, in their 
cytoplasmic secretory granules. Mast cell 
activation can be triggered by IgE-medi-
ated crosslinking of IgE receptors (Fc-ε-
RI) (Ishizaka et al. 1984), by histamine 
releasing factors secreted by neighboring 
T lymphocytes (Sedgwick et al. 1981) or 
macrophages (Liu et al. 1986), or by com-
ponents of the complement system (C3a, 
C5a) (Metcalfe et al. 1981). Activated 
mast cells expel their cytoplasmic secre-
tory granules in a process of exocytosis 
called degranulation. The secretory gran-
ules, consisting of preformed mediators 
bound to a network of negatively charged 
heparin and chondroitin sulfate PGs, 
become swollen, and their individual 
membranes fuse to form tubular degranu-
lation channels in which the granules 
lie in chains (Rohlich et al. 1971). The 
degranulation channels then open to the 
extracellular fl uid, and the soluble com-
ponents of the granules, such as hista-
mine, diffuse away. In contrast, as shown 
in rat serosal mast cells, the heparin PGs 
and the mast cell-specifi c neutral proteases 
(e.g., chymase and carboxypeptidase 
A) remain tightly bound to each other, 
forming proteolytically active extracellular 
REVIEW OF THE LITERATURE
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”granule remnants” (Kovanen 1993). 
The exocytosed remnants are eventually 
ingested by adjacent phagocytes, such as 
macrophages and SMCs (Kokkonen et al.
1987; Wang et al. 1995). The activated 
and degranulated mast cells reconstitute 
their lost preformed mediators through 
rapid onset of de novo synthesis, so 
allowing formation of new secretory 
granules. Finally, the recovered mast cells 
are ready to participate in a new process 
of activation and degranulation (Dvorak
et al. 1986).
Mediators released from mast cells 
Histamine
Mast cells are the major source of hista-
mine in the tissues (Metcalfe et al. 1997). 
Histamine is a potent vasoactive agent, 
constrictor of bronchial smooth muscle, 
and plays a central role in the immediate 
allergic reactions (Repka-Ramirez et al.
2002). Histamine can also have pro-
infl ammatory and immune-modulatory 
effects (Bachert 2002). Within the mast 
cells histamine is stored in the secretory 
granules bound to heparin PGs (Rohlich
et al. 1971). When mast cells are acti-
vated, histamine is secreted together with 
granules into extracellular space, where it 
rapidly dissociates from the heparin PGs. 
Histamine is also secreted at low levels 
by resting mast cells. 
Mast cell proteoglycans
PGs have a long protein core into 
which side chains of highly sulfated 
glycosaminoglycans (GAG) of varying 
lenghts are covalently attached through 
a specifi c linkage region (Järveläinen et 
al. 2002). Mast cells contain two types of 
PGs, heparin and chondroitin PGs, which 
differ in the nature and sulphation of the 
GAG side chains. The heparin PGs make 
up about 90% of the rat serosal mast cell 
PGs (Katz et al. 1986) and 65% of human 
lung mast cell PGs (Stevens et al. 1988). 
In contrast to other intimal cells, which 
actively synthesize and secrete vascular 
PGs important for proper matrix assembly 
and structural integrity of vascular wall 
(Järveläinen et al. 2002), the mast cell 
produced PGs form the network of the 
intracellular secretory granules, in which 
neutral proteases are embedded. Even-
tually, due to mast cell activation and 
degranulation, also the mast cell derived 
PGs are released into the extracellular 
space. Interestingly, heparin PGs appear 
to protect the embedded proteases from 
inactivation, allowing them to remain ac-
tive even in the extracellular fl uid, con-
taining physiological inhibitors of mast 
cell proteases (Pejler et al. 1995; Lindst-
edt et al. 2001a). 
Mast cell proteases
Neutral proteases, i.e., enzymes that are 
proteolytically active at physiological 
pH, are the main product of mast cell 
biosynthetic machinery and may account 
for 20-50% of the total mast cell protein 
(Schwartz et al. 1984). Three main prote-
ases have been purifi ed from human mast 
cells: tryptase, chymase and carboxy-
peptidase A (CPA). In addition, TC-type 
mast cells also contain a cathepsin G-like 
protease (Schechter et al. 1990). 
Tryptase is a trypsin-like neutral serine 
endoprotease, which is enzymatically 
active only in a form of tetramer and 
requires heparin or chondroitin sulphate 
for stability (Schwartz et al. 1986; Lindst-
edt et al. 1998). Tryptase cleaves protein 
and peptide substrates on the carboxyl 
side of Arg and Lys residues. A distin-
guishing feature for tryptase is resistance 
to inhibition by most natural protein 
inhibitors of serine proteinases (Smith et 
al. 1984). Actually, according to current 
notion, there are no physiological 
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inhibitors to this protease. Rather, tryp-
tase becomes inactive in the extracellular 
fl uid when the tetramer dissociates into 
monomers.
Chymase is a 28 kDa neutral serine endo-
protease with a chymotrypsin-like activity. 
It cleaves the peptide or ester bonds at the 
carboxyl terminus of aromatic (Phe, Tyr, 
Trp) or branched-chain aliphatic (Leu, Ile, 
Val) amino acids. Accordingly, chymase 
has been shown to proteolyze several 
types of molecules present in the arterial 
intima. Chymase-mediated proteolysis 
can lead to activation or inactivation 
of bioactive molecules, such as matrix 
metalloproteinases (MMPs) (Saarinen
et al. 1994; Johnson et al. 1998), TGF-
β (Taipale et al. 1995), angiotensin I 
(Kokkonen et al. 1997), certain apoli-
poproteins (Lindstedt et al. 1996), and 
components of the ECM, such as fi bro-
nectin (Vartio et al. 1981) and vitronectin 
(Banovac et al. 1992).
Mast cell carboxypeptidase A is a 34.5 
kDa neutral zinc metallo-exopeptidase, 
which cleaves C-terminal residues with 
hydrophobic side chains (Phe, Tyr, Leu). 
CPA has a complementary specifi city to 
chymase, indicating that they can act se-
quentially to degrade target proteins (Wood-
bury et al. 1981; Kokkonen et al. 1986).
Other bioactive mediators secreted by 
mast cells
Mast cells synthesize and secrete a vari-
ety of mediators, which are vasoactive, 
or regulate infl ammation and cellular 
growth. These include prostaglandin D
2
, 
leukotrien C
4
, leukotrien B
4
, tumor necro-
sis factor-α (TNF-α), transforming growth 
factor-β (TGF-β), and interleukins -4, -5, 
-6, and –13 (Young et al. 1987; Ra et al.
1994). TNF-α is a key cytokine in allergic 
infl ammation, and is also a potent inducer 
of apoptosis (Rath et al. 1999). TGF-β 
regulates proliferation, differentiation and 
death of various cell types (Moustakas et 
al. 2002) and, among other functions, it is 
thought to play an anti-infl ammatory role 
in atherogenesis (Lutgens et al. 2002).
Mast cells and 
atherosclerosis
Mast cells are present in normal human 
blood vessels as well as in atherosclerotic 
lesions, where they form a part of the 
infl ammatory cell infi ltrate (Stary 1990; 
Kaartinen et al. 1994a). The numbers of 
mast cells increase as atherosclerotic le-
sions develop (Kaartinen et al. 1998), but 
the exact triggers that lead to increased 
infi ltration of mast cells are currently 
unknown. One of the possible candi-
dates is eotaxin, a chemotactic factor for 
eosinophils, macrophages and mast cells, 
which is present in atherosclerotic lesions 
(Haley et al. 2000). 
Infl ammation is currently thought to play 
a central role in the initiation and progres-
sion of atherosclerosis (Ross 1999; Libby 
2002). Since the number of activated 
mast cells is increased in culprit lesions in 
patients with unstable coronary syndromes 
(Kaartinen et al. 1998), the possibility 
exists that mast cells could participate 
in the pathogenesis of atherosclerosis. 
Indeed, there is increasing evidence that 
mast cells play a role in infl ammatory cell 
recruitment, foam cell formation and gen-
esis of unstable plaques (Kovanen 1995; 
Kelley et al. 2000). 
Recruitment of infl ammatory cells
Adhesion of circulating monocytes to 
endothelium is one of the earliest steps in 
atherosclerosis (Li et al. 1993b). Their entry 
into the arterial intima depends on the 
interaction with the adhesion molecules on 
the surface of ECs. As mentioned above, 
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activated mast cells secrete a variety of 
pro-infl ammatory substances (Bradding 
1996), many of which, like TNF-α (Pober
et al. 1986), tryptase (Compton et al.
2000), and histamine (Burns et al. 1999), 
can activate ECs to induce expression of 
adhesion molecules, such as P-selectin 
and VCAM-1, responsible for the recruit-
ment of monocytes and lymphocytes (see 
Fig 2 A). Mast cells also stimulate MCP-1 
production in fi broblasts through TNF-
α and TGF-β (Gordon 2000), which, in 
turn, could increase monocyte penetration 
into intima. Thus, mast cells could partici-
pate in the initiation of atherosclerosis by 
recruiting monocytes and lymphocytes 
into the vascular intima (see Fig 2 B).
Neutrophil infi ltration has recently been 
shown to occur in culprit lesions in acute 
coronary syndromes (Naruko et al. 2002), 
but the triggers of this phenomenon are 
unknown. Both human mast cell tryptase 
(He et al. 1997) and chymase (He et al.
1998) have been shown to lead to en-
hanced recruitment of neutrophils into the 
skin of guinea pigs, but the relevance of 
these fi ndings in humans is unknown. The 
possibility exists that mast cells could 
play a role in neutrophil recruitment.
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Figure 2. Effects of mast cells on the development of atherosclerotic lesions. 
Mast cells have been proposed to play a role in recruitment of infl ammatory cells to arterial intima by A.)
increasing expression of adhesion molecules in endothelial cells and B.) increasing migration of mono-
cytes into intima through stimulation of  monocyte chemoattractant peptide-1 (MCP-1) production. Mast 
cells also increase cholesterol accumulation and foam cell formation in the intima by C.) increasing LDL 
infl ux into intima through granule remnant-mediated uptake of LDL and D.) decreasing cholesterol effl ux 
from intima through degradation of preβ-HDL.
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Mast cells contribute to foam 
cell formation
In atherosclerotic lesions, mast cells 
often reside in close association with 
macrophages and extracellular lipids, as 
well as at the sites of foam cell formation 
(Kaartinen et al. 1994b; Jeziorska et al.
1997), suggesting a role for mast cells 
in foam cell formation. The “balance 
theory” of atherogenesis suggests, that 
cholesterol, carried into the arterial intima 
by plasma LDL particles, is recirculated 
back to the circulation by plasma HDL 
particles. Thus, cholesterol accumulation 
and foam cell formation could result from 
an imbalance between these two processes 
(Kovanen 1990). Increasing evidence 
shows that mast cells can contribute to 
the transformation of macrophages and 
SMCs to foam cells in vitro by disturbing 
the balance between cholesterol uptake 
and effl ux.
In order to enter the intima, LDL particles 
must cross the arterial endothelium, 
which acts as a barrier against lipoprotein 
particles (Stender et al. 1981). Histamine 
from mast cells is known to enhance 
vascular permeability to macromolecules 
(Wu et al. 1992), suggesting that activated 
mast cells could loosen the endothelial 
barrier and thus, increase the intimal con-
centration of LDL particles. So far, there 
is no experimental evidence supporting 
this notion in human coronary arteries. 
However, in an animal model of passive 
cutaneous anaphylaxis, a local activation 
of skin mast cells have been shown to result 
in acute and massive accumulation of 
blood LDL in the area in which the mast 
cells were activated to secrete vasoactive 
components, such as histamine (Ma et al.
1997).
Mast cells also increase the uptake of 
LDL by macrophages and SMCs. Briefl y, 
the heparin PGs of mast cell granule rem-
nants bind LDL-particles, which facili-
tates chymase-mediated degradation of 
apolipoprotein B in LDL. This results in 
the fusion of the LDL particles into larger 
lipid droplets and accumulation of LDL 
on granule remnants. Granule remnants 
coated with fused LDL particles are then 
phagocytosed by the macrophages and 
SMCs, leading to increased formation of 
foam cells (Kokkonen et al. 1987; Kok-
konen et al. 1989; Wang et al. 1995; Piha
et al. 1995). Moreover, soluble heparin 
PGs released from activated mast cells 
stimulate scavenger receptor- mediated 
uptake of LDL into macrophages (Lindst-
edt et al. 1992) (see Fig 2 C).
Effl ux of cellular cholesterol is promoted 
by extracellular cholesterol acceptors, 
most notably small discoidal lipid-poor 
preβ-migrating high density lipoproteins 
(preβ-HDL) (Lee et al. 1992). Mast cell 
chymase can proteolyze the apolipo-
protein A-I of preβ-HDL. This leads to 
reduced effl ux of cholesterol from the 
foam cells, thus increasing cholesterol 
deposition in the macrophages present 
in atheromas (See Fig 2 D) (Lee et al.
1992; Lindstedt et al. 1996; Lee et al.
1999). Moreover, mast cell tryptase 
also degrades apoliproteins of HDL and 
blocks its function as an acceptor of 
cholesterol (Lee et al. 2002). The clinical 
signifi cance of these mast cell -mediated 
effects on cholesterol metabolism is still 
unknown.
Mast cells and plaque destabilization
The most important mechanism of sudden 
onset of coronary syndromes, including 
unstable angina, acute myocardial infarc-
tion and sudden cardiac death, is erosion 
or rupture of a coronary atheroma (Fuster
et al. 1992; Falk 1992; Virmani et al.
2000). Increased number of activated 
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mast cells have been found at the site of 
the atheromatous rupture in patients who 
have died of acute myocardial infarc-
tion (Kovanen et al. 1995), and there 
is increasing evidence that mast cells 
could play a role in the destabilization of 
plaques. 
The stability of the plaques depends on 
the thickness of the fi brous cap overlay-
ing the lipid-rich core. The cap consists 
of SMCs and ECM, mostly collagen, 
produced and maintained by SMCs (Lee
et al. 1997). Thus, the processes that 
decrease SMC number, inhibit SMC 
collagen synthesis or increase the ECM 
degradation tend to destabilize the plaque. 
A decrease in SMC number could be due 
to lowered proliferation of SMCs, or their 
increased elimination, e.g. by apoptosis.
Mast cell- derived heparin PGs have been 
shown to inhibit the proliferation of rat 
SMCs in vitro (Wang et al. 1999), sug-
gesting that mast cells could participate 
in the regulation of SMC growth also in 
atherosclerosis (see Fig 3 A). However, 
since the rate of proliferation of SMCs in 
atherosclerotic lesions is rather low (Pick-
ering et al. 1993), the clinical signifi cance 
of such a mechanism in plaque stability 
is likely to be small. Under conditions 
of low proliferation, SMC numbers are 
largely controlled by cell death, either 
through necrosis or apoptosis. Some of 
the mediators released by mast cells are 
Figure 3. Effects of mast cells on plaque stability 
Mast cells may reduce the stability of atherosclerotic plaques through several mechanisms. In vitro they 
have been shown to A.) inhibit proliferation of SMCs, and to B.) synthesize and activate MMPs capable 
of ECM degradation. Moreover, several mast cell-derived mediators, such as chymase and TNF-α are 
proapoptotic, raising the possibility that C.) mast cells might induce SMC apoptosis.
���������
���� ����
�������������
���
��������
�������
������
���
�������
���
����� ���
�
���� �
�����
�����������
�������� �����
�������� ���� �
��
��
�������
�������
��������������� ������
���������
���
���
�������
�
����
22
REVIEW OF THE LITERATURE REVIEW OF THE LITERATURE
proapoptotic, such as chymase, which 
induces cardiomyocyte apoptosis (Hara et 
al. 1999), and TNF-α, which triggers EC 
apoptosis (Slowik et al. 1997). This raises 
the possibility that mast cells could also 
induce apoptosis of SMCs and, by this 
way affect plaque stability (see Fig 3 C).
Matrix metalloproteinases (MMPs) are 
thought to play a prominent role in the 
degradation of the ECM components in 
atherosclerosis and to contribute to cap 
rupture and erosion (Galis et al. 1994; Li-
jnen 2002). By releasing TNF-α, a potent 
proinfl ammatory cytokine (Kaartinen et 
al. 1996), mast cells can induce synthe-
sis and release of the 92 kDa gelatinase 
(MMP-9) from adjacent macrophages in 
paracrine fashion (Saren et al. 1996), and 
from the TNF-α containing mast cells in 
autocrine fashion (Baram et al. 2001). 
Moreover, TNF-α has also been shown to 
increase the expression of collagenase-1,
stromelysin-1 and 92 kDa gelatinase 
in endothelial cells (Nelimarkka et al.
1998). Mast cells also synthesize and 
release interstitial collagenase (MMP-1)
(Di Girolamo et al. 2000), which has 
been found in atherosclerotic lesions 
(Nikkari et al. 1995).
MMPs are synthesized and secreted as 
zymogens, i.e., as inactive proenzymes 
(proMMPs), and, consequently, have to 
be activated after secretion (Birkedal-
Hansen et al. 1993). Chymase and tryp-
tase, the two major neutral proteases 
of human mast cells, are both capable 
of activating MMPs in vitro, chymase 
activating proMMP-1 (Saarinen et al.
1994) and tryptase activating prostrome-
lysin (proMMP-3) (Gruber et al. 1989). 
MMP-3, in addition to being a powerful 
matrix-degrading enzyme, can activate 
other proMMPs, thus triggering a more 
extensive degradation of the surrounding 
ECM (see Fig 3 B). In addition, chymase 
and tryptase can directly degrade ECM 
components, such as fi bronectin and 
vitronectin (Vartio et al. 1981; Lohi et al.
1992).
Benefi cial effects of mast cells in 
atherosclerosis
Mast cells may also have benefi cial effects 
in atherosclerosis. Heparin PGs released 
from activated mast cells strongly prevent 
collagen-induced platelet aggregation 
(Lassila et al. 1997; Kauhanen et al.
2000), and may thus attenuate the throm-
bogenicity of the exposed matrix collagen. 
Mast cell tryptase can interfere with 
coagulation by degrading fi brinogen 
(Schwartz et al. 1985) and procoagulative 
kininogen (Maier et al. 1983), which 
could slow thrombus formation at the 
sites of plaque rupture. Moreover, rat 
serosal mast cells have been shown to 
block copper-mediated oxidation of LDL 
in vitro (Lindstedt et al. 1993). Thus, 
mast cells are also antithrombotic and 
antioxidative cells.
Apoptosis 
Physiological role of apoptosis 
Multicellular organisms need to effi ciently 
dispose cells that are no longer needed or 
that have been damaged. This is accom-
plished through apoptosis, an active form 
of cell death fi rst recognized in 1972 by 
Kerr, Wyllie and Currie in a landmark 
paper (Kerr et al. 1972). Apoptosis counter-
balances cell division and cell migration 
in the maintenance of homeostasis of 
tissue mass, and it also contributes to 
many fundamental biological processes, 
including morphogenesis (Koseki et al.
1992; Raff et al. 1993) and remodeling of 
mature tissues (Polunovsky et al. 1993). 
Apoptosis is also needed to purge the 
body from pathogen-invaded cells and to 
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eliminate auto-aggressive immune cells. 
Inadequate or excessive apoptosis may 
lead to pathological processes, includ-
ing developmental defects, autoimmune 
diseases, neurodegenerative diseases, or 
cancer. Lately, apoptosis has also gener-
ated interest in the pathophysiology of 
atherosclerosis (Kockx et al. 1998; Mallat
et al. 2001; Bennett 2002).
Apoptosis is distinct from the conven-
tional type of cell death, i.e., necrosis, in 
that it has different morphological and 
biochemical properties. Necrosis is a vio-
lent form of cell death and can be caused 
by a range of noxious chemicals, biologi-
cal agents, or physical damage. Necrosis 
is characterized by swelling of cellular 
organelles and cytoplasm, rupture of the 
cellular membranes and disintegration 
of the cell. During necrosis the cytosolic 
proteins of the dying cell are released 
into the intercellular space, initiating an 
infl ammatory response (Wyllie 1997). In 
contrast to necrosis, apoptosis is a co-
ordinated process requiring active par-
ticipation of the dying cell. The classical 
morphological signs of apoptosis include 
cell shrinkage, membrane blebbing, 
chromatin condensation, and fragmenta-
tion of the nucleus into discrete masses 
scattered throughout the cell cytoplasm 
(Wyllie et al. 1980). During apoptosis the 
phospholipid content of the outer cellular 
membrane changes and phosphatidylser-
ine molecules become exposed (Fadok et 
al. 1992). Surrounding cells and macro-
phages recognize this change and rapidly 
engulf the apoptotic cell or its membrane-
enclosed remains, the apoptotic bodies. 
As a consequence, apoptosis evokes little 
if any infl ammatory response, unless the 
clearance of apoptotic bodies fails, in 
which case secondary necrosis ensues 
and infl ammation is initiated. Secondary 
necrosis together with the observation 
that same stimuli can induce both apop-
tosis and necrosis at different conditions 
or even simultaneously (Dypbukt et al.
1994), makes the boundary between 
apoptosis and necrosis somewhat blurred, 
but in most cases a distinction is possible.
Regulation of apoptosis
Apoptosis is tightly regulated to avoid 
inadvertent self-destruction of the cells 
(Hengartner 2000). Apoptosis can be 
initiated by a wide variety of signals, 
including activation of death receptors, γ-
irradiation, hypoxia and UV light. These 
proapoptotic signals are processed by the 
cell and evaluated against anti-apoptotic 
factors, such as growth factor stimulation, 
hormones and attachment to neighboring 
cells before the decision to commit apop-
tosis is made. Most cells need constant 
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Figure 4. Death receptor-mediated apoptotic pathway
Activation of the plasma membrane death receptors, 
such as Fas or TNFαR, by their ligands leads to 
adapter protein (e.g. TRADD) mediated recruitment 
and subsequent activation of initiator caspase-8. 
Active caspase-8 then activates downstream effector 
caspases, which are responsible for the proteolytic 
cleavage of cytoskeletal components, nuclear 
proteins and lamins, leading to changes characteristic 
for apoptosis and fi nally to cell disassembly .
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anti-apoptotic stimulation to survive, 
and withdrawal of these signals leads 
to apoptosis. This enables multicellular 
organisms to dispose cells that either have 
lost their anchorage or are located in a 
nonpermissive environment. 
There are two major pathways leading 
to the initiation of apoptosis: the death 
receptor or extrinsic pathway, and the 
mitochondrial or intrinsic pathway. 
Activation of the plasma membrane 
death receptors of the tumor necrosis 
factor receptor (TNF-R) family, such as 
Fas or TNFαR, leads to adapter protein 
-mediated recruitment and subsequent 
activation of the initiator caspase-8 (Chen
et al. 2002). Caspases form a family of 
highly conserved cysteine proteases that 
initiate and execute the program of cell 
death (Cohen 1997). Activated caspase-8 
activates downstream effector caspases 
(caspase-3, -6, -7) that are directly 
responsible for the proteolytic cleavage of 
cytoskeletal components, nuclear proteins 
and lamins, which then leads to changes 
characteristic for apoptosis and fi nally to 
cell disassembly (see Fig 4). In addition 
to death receptors, caspase-8 can also be 
activated by unligated integrins (Stupack
et al. 2001). Thus, by overexpressing cy-
toplasmic domains of β1 and β3 integrins 
the authors were able to induce caspase-8 
mediated apoptosis of COS7 cells.
In the mitochondrial pathway, apoptosis 
is initiated by a release of mitochondrial 
cytochrome c and other pro-apoptotic 
molecules into the cytoplasm (Chen et al.
2002; Mayer et al. 2003). The association 
of cytochrome c with an adaptor molecule 
Apaf-1 and procaspase-9 leads to the 
formation of active caspase-9 and sub-
sequent effector caspase activation (see 
Fig 5). The release of cytochrome c from 
mitochondria is regulated by the balance 
of the pro- and anti-apoptotic proteins of 
the bcl-2 superfamily. Signals as diverse 
as DNA damage, irradiation, growth 
factor deprivation, and loss of adhesion 
to neighboring cells affect the balance 
within bcl-2 family, and can lead to apop-
tosis. Although the death receptor and the 
mitochondrial pathway are distinct, there 
is crosstalk between them. For instance, 
activated caspase-8 can activate pro-
apoptotic bid of the bcl-2 family, leading 
to activation of the caspase-9 pathway 
(Li et al. 1998).
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Figure 5. Mitochondrial apoptotic pathway
Diverse apoptotic signals, such as DNA damage, 
irradiation, growth factor deprivation, and loss of 
adhesion to neighboring cells are able to initiate 
apoptosis by changing the balance between the 
pro- and antiapoptotic members of bcl-2 super-
family. Shift in balance to proapoptotic members 
leads to release of mitochondrial cytochrome C and 
other pro-apoptotic molecules into the cytoplasm. 
Together with apaf-1 cytochrome C binds procas-
pase-9 forming an apoptosome, which is able to 
activate caspase-9, resulting in effector caspase 
activation. 
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Apoptosis in the vessel wall
Apoptosis is important in the regulation 
of homeostasis and remodeling, as well 
as in a variety of diseases. Apoptosis of 
SMCs is a prominent feature of blood 
vessel remodeling during normal devel-
opment (Walsh et al. 2000), underlying 
for instance closure of ductus arteriosus 
(Slomp et al. 1997), reduction of the 
lumen size of umbilical arteries after the 
birth (Cho et al. 1995), and remodeling 
of the embryonic mammalian pharyngeal 
arch artery system (Molin et al. 2002). 
Apoptosis occurs also at the branch points 
of great arteries arising from the aortic 
arch in human neonates, when they are 
exposed to disturbed blood fl ow (Kim et 
al. 2000). Apoptosis during remodeling 
appears to be triggered by changes in 
blood fl ow and wall tension. Both de-
creased fl ow, perturbations in the fl ow 
(Cho et al. 1997), as well as changes 
in the wall tension (Bayer et al. 1999) 
induce apoptosis of SMCs, allowing the 
vasculature to adapt to new conditions. In 
contrast, normal vessel wall demonstrates 
very low apoptotic and mitotic indices.
Extensive research on balloon angioplasty 
has provided a wealth of information 
regarding arterial injury and apoptosis. 
In animal models, a burst of medial SMC 
apoptosis is observed early after balloon 
distention injury (Perlman et al. 1997), 
resulting in a decreased cellularity. Days 
and weeks later this initial apoptosis is 
followed by a second wave of SMC ap-
optosis in the developing neointima (Han
et al. 1995). Apoptosis induced by arterial 
injury appears to be related to the extent 
of the insult, as increased balloon-to-
artery ratios result in greater frequencies 
of SMC apoptosis (Rivard et al. 1999).
Apoptosis of vascular SMC is also thought 
to participate in development of aneurysms. 
Formation of arterial aneurysms involves 
degradation of collagen, elastin, and vas-
cular PGs, the major structural elements 
of the vessel wall, and loss of SMCs from 
the vessel media. MMPs and other matrix 
degrading enzymes are thought to play 
a critical role in aneurysm formation. 
Lately apoptosis of SMCs has emerged 
as a possible additional factor (Thompson
et al. 1997). Thus, apoptosis of SMCs 
has been shown to occur in abdominal 
(Holmes et al. 1996) and cerebral (Kondo
et al. 1998) aneurysms and aneurysm 
formation is associated with an increase 
in pro-apoptotic molecules (Henderson
et al. 1999). This would weaken the wall 
and favor aneurysm formation due to loss 
of synthesis of ECM components, such as 
collagen, elastin and PGs.
Apoptosis in atherosclerotic 
lesions
Apoptosis has recently generated much 
interest among scientists studying the 
pathogenesis of atherosclerosis (Kockx
et al. 2000; Mallat et al. 2001; Bennett 
2002). Thus, apoptosis has been pro-
posed to play a role in the development 
of atherosclerotic plaques (Bennett et 
al. 1995; Kockx et al. 1998), in the 
generation of procoagulant microparticles 
(Mallat et al. 1999), and in plaque rup-
ture (Kolodgie et al. 2001). Apoptosis 
of SMCs, macrophages and ECs has 
been observed in atherosclerotic lesions 
(Kockx et al. 1998; Tricot et al. 2000), 
and these apoptotic cells are often associ-
ated with the infi ltrates of infl ammatory 
cells (Crisby et al. 1997). The frequency 
of apoptotic cell death seems to increase 
as atherosclerotic plaques develop. Early 
lesions tend to have few apoptotic cells, 
whereas advanced atherosclerotic plaques 
show increased apoptosis (Kockx et al.
1998). Moreover, increased SMC apopto-
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sis has been detected in unstable lesions 
compared with stable lesions of human 
coronary arteries (Bauriedel et al. 1999).
Apoptosis of smooth muscle cells 
The SMCs produce most of the ECM in 
plaques. Thus, their apoptosis would be 
detrimental to plaque stability, as it would 
lead to the loss of collagen and, subse-
quently, to the loss of the mechanical 
integrity of the plaque. SMCs from 
human atherosclerotic plaques show 
relatively low values of cell replication 
(Pickering et al. 1993), and thus modest 
increase in the apoptotic rate could lead to 
a signifi cant decrease in SMC content. An 
important observation is that the SMCs 
isolated from human coronary atheroscle-
rotic plaques are more prone to apoptosis 
compared to SMCs from normal vessels 
(Bennett et al. 1995), and that they show 
strong expression of the pro-apoptotic 
protein bax (Kockx et al. 1998).
Several possible triggers of SMC apopto-
sis are present in atherosclerotic lesions. 
These include infl ammatory cells, certain 
cytokines, and oxidized lipids (Geng et 
al. 2002). Infl ammatory cells can trig-
ger SMC apoptosis in vitro by cell-cell 
interactions (Geng et al. 1997; Boyle et 
al. 2002; Seshiah et al. 2002), and also by 
secreting pro-apoptotic cytokines, such 
as TNF-α (Niemann-Jonsson et al. 2001). 
Modifi ed lipids, especially oxidized LDL, 
have been shown to induce SMC apop-
tosis in vitro (Taguchi et al. 2000). The 
importance of these mechanisms in trig-
gering SMC apoptosis in atherosclerotic 
lesions in vivo is still unknown. However, 
the close spatial relationship between 
apoptotic SMCs and infl ammatory cells 
(Kockx et al. 1998) suggests, that infl am-
matory mechanisms are likely to partici-
pate in the regulation of SMC apoptosis 
in vivo.
Apoptosis of macrophages
Macrophages promote apoptosis of 
SMCs and are responsible for metallo-
proteinase-mediated collagen breakdown 
in atherosclerotic lesions. Accordingly, 
apoptosis of macrophages in atheroscle-
rotic lesions is expected to have a positive 
effect on plaque stability (Kockx et al.
2000). However, macrophages are im-
portant phagocytotic cells and their loss 
would also decrease the scavenging of the 
apoptotic bodies in plaques, leading to 
extracellular accumulation of the apoptotic 
bodies with ensuing complement and 
thrombin activation. Moreover, excessive 
apoptosis of macrophage foam cells could 
contribute to the formation of the lipid 
core (Hegyi et al. 1996).
Macrophages are resistant to several trig-
gers of apoptosis, including FasL (Perl-
man et al. 1999), and they tolerate high 
levels of oxidative stress. The exact trig-
gers of macrophage apoptosis in athero-
sclerotic lesions in vivo are not known, 
and it is likely that several factors, such 
as oxidative stress and cytokines, are 
acting together to induce macrophage 
apoptosis. Tumor suppressor gene p53 
mediated apoptosis is supposed to be 
important in macrophage death. APOE*3-
leiden mice, an animal model for hu-
man-like atherosclerosis, show decreased 
apoptosis and increased lesion area, when 
their macrophages are rendered defi cient 
of p53 through irradiation and bone mar-
row reconstitution from p53(-/-) donor 
mice (van Vlijmen et al. 2001).
Apoptosis of endothelial cells
EC apoptosis has been suggested to con-
tribute to atherogenesis, plaque erosion 
and acute coronary syndromes (Dimmeler
et al. 2002). Atherosclerotic plaques tend 
to develop in the areas with increased EC 
turnover rates, and apoptosis has been 
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suggested to be involved in this (Dim-
meler et al. 1998; Choy et al. 2001). 
EC apoptosis is also one of the possible 
mechanisms leading to plaque erosion 
(Dimmeler et al. 2002). Apoptotic ECs 
are procoagulant (Bombeli et al. 1997) 
and may thus contribute to thrombosis in 
acute coronary events (Dimmeler et al.
2002).
ECs in the normal arterial wall are very 
resistant to apoptosis (Polunovsky et al.
1994; Bach et al. 1997), suggesting that 
special pathological conditions are required 
for the induction of EC apoptosis. Shear 
stress appears to be an important anti-
apoptotic factor for ECs (Dimmeler et 
al. 1996), and in human atherosclerotic 
lesions, the incidence of EC apoptosis 
is higher in the downstream parts of 
plaques, where low fl ow and low shear 
stress prevail (Tricot et al. 2000). Inter-
estingly, most of the classic risk factors 
for atherosclerosis, such as oxidized LDL 
(Dimmeler et al. 1997), smoking (Wang
et al. 2001), and high glucose concentra-
tion (Ho et al. 2000) have been shown to 
be associated with EC apoptosis in vitro.
However, the proof of the clinical relevance 
of EC apoptosis in atherosclerosis is still 
missing (Dimmeler et al. 2002).
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Mast cells form a fraction of the infl ammatory cell infi ltrate in atherosclerotic lesions, and an increased number of activated mast cells is present at the sites of plaque 
rupture or erosion in patients that have died of acute myocardial infarction (Kovanen
et al. 1995). These observations raise the possibility that mast cells might affect the 
stability of coronary atheromas. 
One of the possible mechanisms causing the rupture or erosion of coronary plaques is 
the apoptotic loss of SMCs and ECs, respectively. In atherosclerotic plaques, apoptotic 
SMCs are often located in the areas rich in mast cells and other infl ammatory cells 
(Crisby et al. 1997; Kockx et al. 1998), raising the possibility that mast cells contribute 
to apoptosis of SMCs. Moreover, several mast cell-derived mediators, such as chymase 
(Hara et al. 1999) and TNF-α (Slowik et al. 1997) have proapoptotic properties.
The aim of this thesis work was to study the possible role of mast cells in inducing 
SMC and EC apoptosis. Specifi cally, we wanted to answer the following questions:
1. Are mast cells able to induce apoptosis of cultured SMCs and/or ECs?
2. If so, what are the mast cell-derived pro-apoptotic factors and by which 
mechanisms is apoptosis induced.
3. Are there other mechanisms by which mast cells can affect the growth and function 
of cultured SMCs?
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Isolation of mast cell- 
derived factors 
Animals
Male Wistar rats (300 – 500g) were from the Laboratory Animal Center 
of the University of Helsinki. The rats 
were treated in accordance with institu-
tional guidelines, which had been ap-
proved by the institutional Ethics Com-
mittee.
Isolation and stimulation of 
mast cells
Serosal mast cells were isolated from 
pleural and peritoneal cavities of rats as 
described previously (Kokkonen et al.
1985), and stimulated with compound 
48/80, a noncytotoxic mast cell-specifi c 
stimulator (Lindstedt et al. 1992). After 
stimulation, the cells were sedimented 
by centrifugation at 800g for 5 minutes. 
The supernatant, which contains all the 
material released from the stimulated 
mast cells, will be referred to in the text 
as “mast cell releasate” (see Fig 6). The 
degree of mast cell degranulation was 
determined by measuring the histamine 
content of the releasate (Kokkonen et al.
1985).
Preparation of granule remnants 
and granule remnant-free releasate
To sediment granule remnants, the mast 
cell releasate was centrifuged at 13,000g 
for 10 minutes. After centrifugation, 
the supernatant, which contains all the 
soluble material of the mast cell releas-
ate, was collected, and used as “granule 
remnant-free releasate”. The sedimented 
granule remnants were washed twice 
with water, resuspended in PBS, and used 
as “granule remnants” (see Fig 6). The 
concentration of the granule remnants is 
expressed in terms of their total protein 
content, or of their chymase activity, 
using N-benzoyl-tyrosine ethyl ester 
(BTEE) as substrate (Woodbury et al.
1981).
Purifi cation of heparin 
proteoglycans, chymase and 
carboxypeptidase A
To dissociate the two neutral proteases 
chymase and carboxypeptidase A (CPA) 
from the heparin PGs, isolated granule 
remnants were incubated in high-salt 
buffer consisting of 10 mmol/L phosphate 
buffer supplemented with 2 mol/L KCl, 
pH 7.0. The mixture was then applied to a 
Sephacryl S-200 HR column, and eluted 
with the same high salt buffer. Fractions 
containing Alcian blue-reactive material 
were collected, dialyzed extensively 
against water, concentrated with a Centri-
con 10 fi lter, and used in the experiments 
(Yurt et al. 1977). These heparin PG frac-
tions were devoid of any protease activ-
ity, as determined by a sensitive method 
involving analysis of the proteolytic prod-
ucts of angiotensin I by reverse-phase 
high-performance liquid chromatography 
(RP-HPLC) (Kokkonen et al. 1997). 
Briefl y, angiotensin I, a peptide highly 
susceptible to chymase degradation, was 
incubated with the sample for 30 min 
and the peptides were then isolated and 
analyzed on RP-HPLC. Angiotensin I-
derived products were identifi ed by com-
parison of their retention times with those 
of synthetic standards.
Fractions containing chymase or CPA 
activity were collected separately, and 
further purifi ed on a HiTrap heparin-
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Sepharose column. The purity of chy-
mase and of CPA was determined by 
SDS-PAGE and RP-HPLC (Kokkonen
et al. 1997). The purifi ed heparin PGs, 
chymase, and CPA were stored at -70°C 
until use.
Production of chymase-generated 
fi bronectin degradation products
To produce FN degradation products, 
commercial FN was incubated at 37ºC ei-
ther for 30 min with proteolytically active 
mast cell granule remnants containing 40 
BTEE units/mL of chymase, or for 2.5 
minutes with 20 BTEE units/mL of puri-
fi ed chymase. After incubation, chymase 
was inactivated by either removing the 
granule remnants by centrifugation (20 
min, 15 000 g) or adding PMSF (1 mmol/
L). The absence of contaminating active 
chymase in the FN degradation products 
was verifi ed by a chromogenic substrate 
(BTEE) and RP-HPLC method (Kokko-
nen et al. 1997).
Cells
Isolation, culture and growth arrest 
of rat aortic smooth muscle cells 
Aortic SMCs were isolated from male 
Wistar rats as previously described (Wang
et al. 1999). The cells were seeded into 
25 cm2 Falcon polystyrene tissue culture 
fl asks at a density of 2 x 104 cells/cm2 in 
5 mL of RPMI 1640 culture medium sup-
plemented with 2 mmol/L L-glutamine, 
100 U/mL of penicillin, 100 μg/mL of 
streptomycin, and 10% fetal calf serum 
(FCS), and, at confl uence, were subcul-
tured (1:2) up to nine times. SMCs of the 
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Figure 6. Rat serosal mast cell- derived mediators
Upon stimulation, mast cells exocytose preformed mediators in secretory granules (mast cell releasate). 
Histamine and other soluble mediators diffuse away, whereas heparin proteoglycans and the mast cell-
specifi c neutral proteases remain tightly bound to each other, forming proteolytically active extracellular 
”granule remnants” Components of the granule remnants, e.g. chymase, CPA and heparin proteoglycans 
can be dissociated from each other by high salt and purifi ed by gel fi ltration and affi nity chromatography.
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5th to 9th passages were used in the experi-
ments. To obtain growth-arrested SMCs, 
sparsely seeded SMCs were cultured to a 
subconfl uent cell density in the above cul-
ture medium containing 10% FCS, after 
which they were growth-arrested in 0.4% 
FCS-containing medium for 48 hours 
(Castellot, Jr. et al. 1989).
Culture of human coronary arterial 
smooth muscle cells
Human coronary artery SMCs were 
obtained from Clonetics, cultured in 
SmGM-3 medium and, at confl uence, 
subcultured up to three times, as recom-
mended by the manufacturer.
Isolation and culture of rat 
myocardial endothelial cells
ECs were isolated from rat myocardium 
and cultured as previously described 
(Piper et al. 1990). The cells were identi-
fi ed as ECs by their positive immunos-
taining for von Willebrand factor and 
uptake of DiI-labeled acetylated LDL, 
and the contamination with other cardiac 
cells was found to be less than 1%. The 
ECs were used in experiments between 
the 2nd and 4th passages.
Detection of apoptosis
Microscopic analysis of apoptosis 
Cell smears were stained by the standard 
May-Grünwald-Giemsa method, after 
which apoptotic cells were identifi ed by 
the following criteria: condensation of 
cytoplasm, cell surface blebbing, compac-
tion of chromatin, and fragmentation of 
the nucleus into discrete masses scattered 
throughout the cell cytoplasm (Wyllie
et al. 1980). Alternatively, cell smears 
were stained with 25 µg/mL propidium 
iodide, or with 1 mg/mL Hoechst 33342 
after which the cells were viewed under 
fl uorescence microscope, and cells with 
fragmented nuclei were considered as 
apoptotic. 
Annexin-V-FLUOS staining
Translocation of phosphatidyl serine from 
the inner layer of plasma membrane to 
the outer layer is a common feature in 
many apoptotic cells (Fadok et al. 1998). 
Presence of phosphatidyl serine on the 
cell surface was detected by Annexin-V-
FLUOS staining (0.1 µg/mL) according 
to the manufacturers recommendation.
TUNEL- assay
Apoptotic cells were identifi ed by terminal 
deoxynucleotidyl transferase-mediated 
dUTP nick end labeling (TUNEL) with 
an ApoTag In Situ Apoptosis Detection 
Kit. Briefl y, apoptotic cells were labeled 
with digoxigenin-conjugated dUTP and 
terminal deoxyribonucleotide transferase, 
the labeled DNA fragments were stained 
with anti-digoxigenin monoclonal anti-
body linked with fl uorescein , and viewed 
under fl uorescence microscope.
Flow cytometric analysis of 
apoptosis and cell cycle
The cellular DNA content was determined 
by fl ow cytometric analysis of PI-labeled 
cells (Leszczynski 1995). Briefl y, the 
SMCs attached to the culture dishes were 
detached with trypsin and combined with 
the cells fl oating in the culture medium. 
The cells were then fi xed with methanol, 
incubated with 100 units/mL of RNAase 
and, fi nally, stained with propidium 
iodide (PI). After staining, the cells were 
analyzed with a FACScan, using CellFit 
2.02 software. Fluorescence was measured 
from 10 000 events in list mode. Gating on 
FL2-A versus FL2-W was used to remove 
doublets. Apoptotic nuclei were identifi ed 
as a subgenomic DNA peak and were dis-
tinguished from cell debris by both their 
forward light scatter and the fl uorescence 
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of PI. The cell cycle distribution was 
analysed by CellFit 2.02 software.
DNA fragmentation analysis
DNA was extracted by a standard method 
(Strauss 1987), and equal amounts of 
DNA from each sample were subjected to 
electrophoresis on 1.5% agarose gel for 
3 hours at 80 V in TBE buffer. The gel 
was stained with ethidium bromide, and 
photographed under ultraviolet light.
Analysis of apoptotic 
mechanism
Caspase assays
Activity of caspases -3, -6, -8, and -9 
were analyzed by using fl uorometric 
assay kits. Briefl y, the cells were lysed 
and the lysates were incubated with a 
caspase-specifi c peptide conjugated to the 
fl uorescent reporter molecule. The cleav-
age of the peptide by the caspase releases 
the fl uorochrome that, when excited with 
light, emits fl uorescence directly propor-
tional to the caspase enzymatic activity in 
the cell lysate. Fluorescence was detected 
by a microplate reader. 
Reverse transcriptase -PCR 
analysis of bcl-2 and bax
Total RNA was extracted from EC and 
SMC monolayers, using an ultrapure 
TRIzol reagent; 1-4 µg of RNA was then 
reverse-transcribed into cDNA, using a 
Superscript TM pre-amplifi cation system. 
The cDNA obtained was further amplifi ed 
by PCR with specifi c oligonucleotides 
(see Study IV, Table 1) Competitive 
RT-PCR was performed as previously 
described (Lindstedt et al. 2001b). The 
competitor DNA for bcl-2 was obtained 
by inserting an 143 bp external DNA 
fragment into the BamHI site, whereas 
the competitor DNA for bax was obtained 
by inserting an 124 bp external DNA 
fragment into the NheI site. The use of 
equal amounts of mRNA in the RT-PCR 
assays was confi rmed by analyzing the 
expression levels of glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). The 
PCR fragments obtained were verifi ed to 
represent the corresponding targets either 
by specifi c restriction enzyme treatment 
or by DNA sequencing. The PCR products 
were quantitated with a Gel Doc 2000 gel 
documentation system. 
Detection of cytoplasmic and 
mitochondrial cytochrome c 
ECs were cultured in the presence or ab-
sence of mast cell granule remnants for 6 
hours after which the cells were collected 
and disrupted with a Dounce homogenizer. 
Cytoplasm and mitochondrial fractions 
were isolated as previously described 
(Tafani et al. 2000) and were further sub-
jected to SDS-PAGE and Western blot-
ting, after which the level of cytochrome 
c in the subfractions was measured using 
a polyclonal antibody against cytochrome 
c. The amount of cytochrome c was quan-
tifi ed with a Gel Doc 2000 gel documen-
tation system.
Immunoblotting
The cells were lysed in sodium 
orthovanadate buffer (150 mmol/L NaCl, 
10 mmol/L Tris, pH 7.6, 1% Triton X-
100
, 
5 mmol/L EDTA, 1 mmol/L PMSF, 
2 mmol/L benzamidine, 2.5 μM apro-
tinin, 2.5 μM leupeptin, and 1 mmol/L 
sodium orthovanadate). For each sample, 
40 μg protein was electrophoresed on 
12% SDS-PAGE, transferred to a nitro-
cellulose membrane, and probed with 
either anti-FAK, anti-Akt, anti-p-FAK, 
anti-p-Akt, 4G10 anti-phosphotyrosine 
or anti-NFκΒ antibody. Immunoreactive 
bands were visualized through enchanced 
chemiluminescence with either horserad-
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ish peroxidase (HRP) conjugated rabbit 
anti-mouse IgG (anti-FAK, anti-Akt and 
4G10), HRP-conjugated goat anti-rabbit 
IgG (anti-p-FAK, anti-NFκΒ), or HRP-
conjugated rabbit anti-sheep IgG (anti-p-
Akt). The immunoblots were quantitated 
by densitometric scanning with a Gel Doc 
2000 gel documentation system.
Immunostaining of cells
SMCs and ECs were cultured to sub-
confl uent monolayers on Thermanox 
coverslips, exposed to granule remnants 
or purifi ed chymase and fi xed with 4% 
paraformaldehyde for 10 minutes at room 
temperature. FN was detected using a 
polyclonal antibody and a rabbit-anti-
goat secondary antibody conjugated with 
peroxidase. P-FAK was detected with 
an anti-p-FAK antibody and visualized 
with an Alexa Fluor (546)-labeled goat 
anti rabbit antibody. NFκΒ was detected 
with anti-NFκΒ antibody and visualized 
with biotin-conjugated goat anti-rabbit 
antibody and FITC- conjugated strepta-
vidin. bcl-2 was detected with anti-bcl-2 
antibody, and bax with anti-bax antibody. 
Both were amplifi ed with a biotinylated 
secondary antibody and visualized with 
HRP-conjugated streptavidin with 3-ami-
no-9-ethyl carbazole (AEC) as substrate. 
Immunostaining of smooth muscle 
cell-derived ECM
SMC-derived ECM was prepared by 
sequential extraction with sodium deoxy-
cholate and hypotonic buffer in the pres-
ence of protease inhibitor as previously 
described (Hedman et al. 1979), except 
that the SMCs were cultured on Ther-
manox coverslips. FN was detected using 
a polyclonal antibody and a rabbit-anti-
goat secondary antibody conjugated with 
peroxidase. TGF-β1 was then detected 
with a polyclonal antibody against TGF-
β1 using biotin-streptavidin amplifi cation 
and peroxidase staining, as recommended 
by the manufacturer. 
Electrophoretic mobility shift 
assay (EMSA)
Nuclear proteins were extracted as previ-
ously described (Andrews et al. 1991) 
and electrophoretic mobility shift assay 
was performed with minor modifi cations 
(Pentikäinen et al. 2002). Briefl y, 10 μg 
nuclear extracts were incubated for 60 
minutes at room temperature with 50 
000 cpm of 32P-labeled NFκB consensus 
oligonucleotide probe, which has a bind-
ing site for NFκB/c-Rel homodimeric and 
heterodimeric complexes. The samples 
were run on 4% polyacrylamide gels in 
0.25 x TBE buffer, dried and exposed to 
light sensitive fi lm at –70°C. Competition 
was performed by the addition of 100-fold 
excess nonradioactive oligonucleotide 
competitors before addition of radioactive 
probe. The sequence of NFκB oligonucle-
otides was as follows: 
Consensus 
5’- AGT TGA GGG GAC TTT CCC AGG C – 3’
Unlabeled mutant 
5’- AGT TGA GGC GAC TTT CCC AGG C – 3’
Other assays
Protein was determined by the standard 
Lowry procedure (Lowry et al. 1951). 
The glycosaminoglycan content of 
heparin PGs was determined by assaying 
Alcian blue-reactive material with com-
mercial heparin as standard (Bartold et 
al. 1985). The quantity of TGF-β1 was 
determined by ELISA, as recommended 
by the manufacturer.
Polyacrylamide gel electrophoresis 
and immunoblotting of TGF-β1
Gradient (4 to 20%) sodium deoxycholate-
polyacrylamide gel electrophoresis for 
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detection of active TGF-β1 was carried 
out as described (Taipale et al. 1994). 
Active TGF-β1 was detected with a poly-
clonal antibody against TGF-β1, using 
biotin-streptavidin amplifi cation and ECL 
detection (Taipale et al. 1992).
Competitive RT-PCR analysis of 
TGF-β1, PAI-1, TβRI, TβRII and 
collagen type I and III mRNA
Total RNA was extracted from subcon-
fl uent SMCs using an ultra pure TRIzol 
reagent; 1 µg of RNA was then reverse-
transcribed into cDNA using a Super-
script TM pre-amplifi cation system. The 
cDNA obtained was further amplifi ed by 
PCR with specifi c oligonucleotides (see 
Study II, Methods). The PCR fragments 
obtained were verifi ed to represent the 
corresponding targets by specifi c restric-
tion enzyme treatment and quantitated 
with a Gel Doc 2000 gel documentation 
system. For competitive RT-PCR, com-
petitor DNAs were prepared by insertion 
of a 125-bp external DNA fragment at the 
Pst I site for TGF-β1, a 129-bp fragment 
at the Stu I site for collagen type I, and a 
133-bp fragment at the BamH I site for 
collagen type III, respectively. The PCR 
products for the target and its competitor 
were 350 bp and 475 bp for TGF-β1, 266 
bp and 395 bp for collagen I, and 312 bp 
and 445 bp for collagen type III, respec-
tively.
Determination of DNA synthesis
DNA synthesis was determined by meas-
uring the incorporation of [3H]thymidine 
(1 µCi/mL) into the trichloroacetic acid 
(TCA)- precipitable material of the SMCs 
(Wang et al. 1999). Cell viability of 
chymase-treated SMCs was monitored 
by phase-contrast microscopy with and 
without trypan blue staining of cells.
Statistical analysis
Data, shown as means ± SEM, were 
analyzed with Student’s t test for determi-
nation of the signifi cance of differences, 
which were considered to be statistically 
signifi cant at a P value of less than 0.05.
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Mast cells and smooth 
muscle cell apoptosis
Activated mast cells induce  
smooth muscle cell apoptosis
To investigate whether activated rat serosal mast cells are able to induce 
smooth muscle cell (SMC) apoptosis, we 
prepared mast cell releasate containing all 
the substances released by activated mast 
cells. Growth-arrested rat aortic SMCs 
were exposed to increasing concentra-
tions of mast cell releasate for 24 hours 
and their DNA content was analysed by 
fl ow cytometry. Cells having hypodiploid 
DNA peaks were considered apoptotic. 
As the concentration of mast cell releas-
ate increased, the percentage of apoptotic 
SMCs increased in a dose-dependent 
manner, reaching 11,4% with releasate 
derived from 3.6 x 105 mast cells. (Study 
I, Figure 1 A) The presence of apoptotic 
SMCs in mast cell releasate-treated sam-
ples was further confi rmed by appear-
ance of cells with fragmented nuclei in 
May-Grünwald-Giemsa (MGG) staining 
(unpublished data).
Chymase induces smooth muscle 
cell apoptosis 
To identify the factors responsible for in-
ducing apoptosis of SMCs, we separated 
the mast cell releasate into granule rem-
nants and granule remnant-free releasate. 
The granule remnants induced apoptosis 
of SMCs like the total mast cell releas-
ate, whereas the granule remnant-free 
releasate had no signifi cant effect (Study 
I, Figure 1 B and C). We further purifi ed 
the three main components of the granule 
remnants, i.e., heparin PGs, chymase, and 
carbocypeptidase A, and examined their 
ability to induce apoptosis of SMCs. It 
was found that, of the total mast cell re-
leasate, only chymase was able to induce 
apoptosis of SMCs (Study I, Figure 2).
The ability of chymase to induce apop-
tosis of SMCs was further confi rmed by 
four independent methods (Study I, 
Figure 3). Chymase-treated SMCs 
showed nuclear fragmentation, as de-
tected by MGG staining, and propidium 
iodide (PI) staining, and stained posi-
tively in TUNEL. In addition, agarose 
gel electrophoresis of the DNA extracted 
from SMCs treated with chymase revealed 
a “ladder” of DNA fragments that consist-
ed of integral multiples of 180-200 base 
pairs, typical for apoptosis.
Purifi ed chymase induced apoptosis of 
SMCs in a time- and dose-dependent 
manner, and apoptosis could be observed 
as early as 2 hours after exposure to chy-
mase (Study I, Figure 4). Chymase also 
induced a clear, concentration-dependent 
decrease in cell numbers in the chymase-
treated samples (unpublished data).
Recombinant human chymase 
induces apoptosis of human 
coronary artery smooth muscle cells
All the above results and the results to be 
reported in the subsequent paragraphs of 
the result section, were obtained by using 
rat as a model system. To investigate the 
relevance of these fi ndings in human sys-
tem, SMCs derived from human coronary 
arteries (CASMC) were exposed to re-
combinant human chymase (rh-chymase). 
Also the rh-chymase was found to induce 
apoptosis of CASMCs as measured by 
fl ow cytometry and confi rmed by TUNEL 
assay (Study I, Figure 5).
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The ability of chymase to induce 
smooth muscle cell apoptosis 
depends on its proteolytic activity
To study whether the proteolytic activity 
of chymase is responsible for the induc-
tion of SMC apoptosis, we exposed 
SMCs to chymase in the presence of 
soybean trypsin inhibitor (TRINH), a 
commercially available serine protease 
inhibitor and measured apoptosis with 
FACS. The activity of chymase was mea-
sured by N-benzoyl-tyrosine ethyl ester 
(BTEE) assay. In the presence of 100 
µg/mL TRINH the proteolytic activity of 
purifi ed chymase (20 BTEE units/mL) 
was fully blocked (0 BTEE units/mL) and 
the proportion of apoptotic cells (18.4% 
± 1.4% in chymase-treated cells) was 
reduced to the basal level (4.2 ± 1.3% 
versus 3.2 ± 0.5% in control cells) The 
TRINH alone was without any effect on 
SMC apoptosis.
Chymase-mediated apoptosis 
involves caspase-8
To obtain information about the intracel-
lular mechanisms of chymase-induced 
apoptosis, SMCs were treated with 
chymase in the presence of a caspase 
inhibitor I (Z-VAD-FMK, 100 µmol/L), 
a broad spectrum inhibitor which has 
been shown to effi ciently inhibit effector 
caspases, such as caspase-3 (Slee et al.
1996; Kawasaki et al. 2000) and caspase-
7 (Chandler et al. 1998). Addition of this 
inhibitor to the SMCs strongly decreased 
the chymase-dependent increase in the 
number of apoptotic cells (Study I, Fig-
ure 6). We next tested whether inhibiting 
caspase-8 or -9, two well-known initia-
tor caspases, would have an effect on the 
chymase-induced apoptosis. Caspase-8 
inhibitor reduced the apoptotic rate by 
about 60%, whereas caspase-9 inhibitor 
was without effect (Study I, Figure 6).
Chymase bound to heparin 
proteoglycans is able to induce 
SMC apoptosis in the presence of 
natural inhibitors
Several natural inhibitors of chymase, such 
as α
1
-antitrypsin, α
2
-macroglobulin, and 
α
1
-antichymotrypsin are present in tissue 
fl uids (Travis J et al. 1983). In order to 
study whether chymase-mediated apopto-
sis can occur under physiological condi-
tions, we incubated SMCs and chymase 
in the presence of serum. For comparison, 
several other neutral proteases were also 
tested for their ability to induce SMC 
apoptosis under similar conditions. In the 
absence of serum all the proteases tested 
induced apoptosis of the growth-arrested 
rat SMCs (Study III, Table 1). However, 
in serum (10% FCS), only the heparin 
PG-bound chymase present in exocytosed 
mast cell granules was able to retain a 
part (~4%) of its apoptotic potential. 
Thus, under conditions mimicking those 
in physiological tissues, i.e., in the pres-
ence of protease inhibitors, chymase in its 
natural form, i.e., when bound to heparin 
PGs, retained a part of its proteolytic 
activity (20 vs. 3.8 BTEE units/mL) and 
was able to induce SMC apoptosis.
Chymase degrades SMC-derived 
fi bronectin
After treating SMCs with proteolytically 
active chymase, the typical cell spreading 
of the SMCs (Study III, Figure 1) was 
found to be disturbed and the cells showed 
a rounded up morphology, suggesting that 
chymase may induce apoptosis by dis-
rupting their interactions with the extra-
cellular matrix (ECM). Since fi bronectin 
(FN) is known to be an important ECM-
component involved in SMC spread-
ing (Hedin et al. 1997), and also to be 
highly susceptible to chymase-mediated 
proteolysis (Vartio et al. 1981), we next 
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studied the effect of chymase on SMC-
derived FN. Untreated SMCs showed 
extensive cell spreading and positive 
perinuclear staining of FN, refl ecting on-
going synthesis of FN. In addition, a light 
diffuse positive staining was seen in their 
pericellular vicinity, indicating secretion 
of synthesized FN (Study III, Figure 1 
C). In contrast, SMCs treated with chy-
mase were retracted and showed intense 
punctate plasma membrane-associated 
staining of FN (Study III, Figure 1 D). 
Furthermore, the light diffuse staining of 
pericellular FN observed in the untreated 
SMCs was lost in the chymase-treated 
SMCs, indicating extensive degradation 
of the extracellular FN. By fi rst detaching 
and removing the cultured SMCs with 
detergents, we could visualize the SMC-
derived intact FN-matrix, which appeared 
as a typical fi brillar layer attaching to the 
cover slips on which the SMCs had been 
cultured (Study III, Figure 1 C, inset). In 
sharp contrast, when such intact FN-ma-
trix was treated with chymase, the fi bril-
lar staining was rapidly lost and intense 
punctate staining appeared, refl ecting 
extensive degradation of the FN chains 
(Study III, Figure 1 D, inset). 
To further analyze the effect of chymase 
on SMC spreading, we stained the SMCs 
with an antibody specifi cally recognizing 
activated, phosphorylated focal adhesion 
kinase (p-FAK), a key component in the 
formation of focal adhesion complexes. 
Normal spreading of SMCs involves the 
active formation of focal adhesion com-
plexes, appearing as focal contacts in the 
plasma membrane of the SMCs (Study 
III, Figure 1 E, arrows). In contrast, 
treatment of SMCs with proteolytically 
active chymase disrupted the focal adhe-
sion complexes, leading to a loss of the 
focal contacts in the plasma membranes 
of the SMCs (Study III, Figure 1 F). 
Interestingly, after chymase treatment, 
p-FAK appeared to accumulate in the 
nuclei of the treated SMCs (Study III, 
Figure 1 F, arrows).
Chymase-generated FN degradation 
products induce SMC apoptosis
To further differentiate between direct 
effects of chymase and possible additional 
effects of chymase-generated FN degra-
dation products on SMC apoptosis, we 
treated commercial plasma-derived FN 
with heparin PG-bound chymase (granule 
remnants). The formed FN degradation 
products were separated from the granule 
remnants by sedimenting the remnants by 
centrifugation, after which the aliquots of 
the protease-free supernatant were added 
to growth-arrested SMCs. The absence 
of contaminating active chymase in the 
FN degradation products was verifi ed by 
a chromogenic substrate (BTEE), and a 
highly sensitive reverse-phase high-
performance liquid chromatography (RP-
HPLC) method (Kokkonen et al. 1997). 
In contrast to untreated intact FN, which 
had no signifi cant effect on the level of 
SMC apoptosis, the FN degradation prod-
ucts were found to induce apoptosis in a 
dose-dependent manner and to a similar 
extent as chymase (Study III, Figure 2). 
Chymase and chymase-generated 
fi bronectin degradation products 
alter the tyrosine phosphorylation 
status in smooth muscle cells
Since ECM components are known to 
regulate cell survival through outside-
in signaling, i.e., by activating protein 
tyrosine kinases in the cell survival 
signaling pathway (Frisch et al. 1996), 
we next studied the effect of chymase 
and chymase-generated FN degradation 
products on the tyrosine phosphorylation 
status in SMCs. Purifi ed chymase induced 
rapid changes (within 10 min) in the level 
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of tyrosine phosphorylation in SMCs, 
and notably, two proteins (~130 kD, ~80 
kD) were markedly less phosphorylated 
(Study III, Figure 3 A, arrows). Further-
more, the chymase-induced SMC apopto-
sis was completely inhibited (chymase 36 
% ±1,5 %, chymase and 500 μM sodium 
orthovanadate 6,8 % ± 0,45 %, control 
5,3 % ± 0,1 %) in the presence of 500 
μM sodium orthovanadate, an inhibitor of 
tyrosine phosphatases, indicating that the 
chymase-mediated SMC apoptosis is trig-
gered by a mechanism involving tyrosine 
dephosphorylation. More importantly, the 
chymase-generated FN degradation prod-
ucts resulted in a dephosphorylation pattern 
similar to that obtained with chymase, 
further suggesting that both chymase and 
the FN degradation products induced 
SMC apoptosis via a similar outside-in 
signaling mechanism (Study III, Figure
3 B).
Chymase disturbs p-FAK-dependent 
survival signal transduction cascade
The observed reduction in tyrosine 
phosphorylation of a 130 kDa molecule 
(Study III, Figure 3A, upper arrow) and 
the loss of focal adhesion complexes 
(Study III, Figure. 1 F), both suggest 
that focal adhesion kinase (FAK) itself 
may be a target of dephosphorylation. In 
order to test this hypothesis, we treated 
SMCs with chymase and the FN degra-
dation products and measured FAK and 
p-FAK protein levels using Western blot-
ting. Both chymase and the FN degrada-
tion products induced a time-dependent, 
strong reduction in the level of phospho-
rylated active FAK (p-FAK) (Study III, 
Figure. 4 A). However, both chymase 
and the FN degradation products also 
induced a similar time-dependent reduc-
tion in the protein level of FAK, suggest-
ing an extensive proteolytic degradation 
of this molecule (Study III, Figure. 4 A). 
The FN degradation products showed a 
somewhat delayed and less strong effect 
in FAK degradation, revealing that deg-
radation of pericellular FN by chymase 
was more effi cient in inducing apoptosis 
than addition of soluble anti-adhesive FN 
degradation products to cells with intact 
pericellular FN. 
To further verify the inhibition of the 
p-FAK-dependent signal transduction cas-
cade, we analyzed the degree of phospho-
rylation and the protein levels of a down-
stream mediator, Akt. Akt is an important 
mediator between extracellular signals 
and modulation of gene expression, me-
tabolism, and cell survival (Scheid et al.
2003). We found that both chymase and 
the FN degradation products (Study III,
Figure 4, panels C and D) induced Akt 
dephosphorylation, whereas neither had 
a signifi cant effect on the level of the Akt 
protein.
Chymase leads to NFκB degradation 
and prevents its tranclocation to 
nucleus
In several cell types, including ECs 
(Scatena et al. 1998; Weaver et al. 2002) 
and neutrophils (Kilpatrick et al. 2002), 
integrin-mediated cell survival signaling 
has been shown to involve the activation 
of nuclear factor kappa B (NFκB). In order 
to test whether the chymase-induced 
SMC apoptosis involves modulation of 
the NFκB signaling system, growth-
arrested rat arterial SMCs attached to 
cytoslides were exposed to 3 BTEE 
units/mL of chymase for 4 hours. The 
cells were then fi xed and stained with an 
anti-NFκB antibody that recognize the 
transactivating p65-subunit of NFκB. It 
was found that both the cytoplasm and 
the nuclei of the control cells stained 
weakly for NFκB (Study V, Figure 1 A, 
RESULTS
39
RESULTS
upper left, arrows), indicating a moder-
ate constitutive activation and nuclear 
translocation of NFκB. In contrast, the 
chymase-treated cells showed no nuclear 
NFκB staining (upper right, arrows), 
indicating impaired nuclear translocation. 
In addition, the chymase-treated cells 
have a retracted morphology (Study III, 
Figure 1 B) explaining the more intense 
perinuclear and cytoplasmic staining 
pattern. To further study the effect of 
chymase on NFκB activation and nuclear 
translocation, SMCs were pretreated with 
chymase for 1.5 hours and then exposed 
to 5 μg/mL lipopolysaccharide (LPS), a 
well known activator of NFκB (Müller
et al. 1993). In the presence of LPS, the 
nuclear staining was intense (Study V, 
Figure 1 A lower left, arrows), refl ect-
ing NFκB activation and translocation to 
nuclei. However, pretreating the SMCs 
with chymase totally abolished the LPS-
mediated nuclear translocation of NFκB 
(Study V, Figure 1 A lower right, arrows). 
By using Western blotting techniques, we 
could show that after chymase-treatment 
(1 hour) the total amount of NFκB, i.e. 
p65 immunoreactivity, was signifi cantly 
decreased (see Study V, Figure 1 B), sug-
gesting that the nuclear translocation is 
lost due to NFκB (p65) degradation. 
Similar to the immunhistochemical re-
sults, electrophoretic mobility shift assay 
(EMSA) analysis of nuclear extracts iso-
lated from untreated SMCs showed a low 
level of constitutive NFκB DNA-binding 
activity (see Study V, Figure 2, lane 1). 
This activity was highly increased when 
the SMCs were treated with LPS (lane 3). 
Furthermore, chymase signifi cantly de-
creased the level of both constitutive and 
LPS-induced NFκB DNA-binding activity 
(lane 4). Together these results suggest that 
chymase, by affecting the total amount 
of NFκB and thereby its activation and 
nuclear translocation, disturbs the NFκB-
mediated cell signaling system. 
Chymase decreases bcl-2 
expression
In terms of apoptosis, one of the target 
genes of NFκB is the antiapoptotic bcl-2,
which is involved in SMC apoptosis 
(Leszczynski et al. 1994). To study the 
effect of chymase on the level and func-
tion of the bcl-2 protein, SMCs were 
cultured on cytoslides, growth-arrested, 
and exposed to chymase for 16 hours. 
Untreated SMCs showed a strong punc-
tate immunostaining for bcl-2 (Study 
V, Figure 3 A, upper left), typical for 
mitochondrial localization. In contrast to 
bcl-2, bax, a proapoptotic protein from 
bcl-2 family, seems to reside mainly in 
the cytoplasm of untreated cells (Study 
V, Figure 3 A lower left). However, after 
chymase-treatment bax translocated to 
the mitochondria as indicated by a more 
punctate staining pattern (Study V, Figure 
3 A lower right), suggesting an activation 
of the mitochondrial death pathway.
In contrast, treatment with chymase 
resulted in a loss of the punctate mito-
chondrial-like staining, leaving only a 
faint cytoplasmic staining. As bcl-2 in 
normal cells is mainly localized to mito-
chondria, these fi ndings suggest a de-
creased bcl-2 content in mitochondria of 
chymase-treated cells. To further analyze, 
whether the loss of mitochondrial bcl-2 
staining is a result of decreased bcl-2 
gene expression, as could be implicated 
by the reduced NFκB activation, we 
measured the level of bcl-2 mRNA in 
the chymase-treated SMCs as a function 
of time. The expression of bcl-2 mRNA 
decreased rapidly after incubation with 
chymase and was maximally inhibited at 
6 hours (See Study V, Figure 3 B). 
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Chymase activates caspase-3, -8, 
and -9
Chymase-induced apoptosis could be 
inhibited with a caspase-8 inhibitor, 
whereas a caspase-9 inhibitor had no effect 
(Study I, Figure 6). In order to directly 
study the activation of caspases, we ex-
posed growth-arrested SMCs to chymase 
for 16 hours and measured the activity of 
caspase-3, -8, and -9 using specifi c fl uores-
cent substrates. Chymase did activate both 
the initiator caspase-8 and -9, and effector 
caspase-3 (Study V, Figure 4). Interest-
ingly, the activity of all 3 caspases was 
inhibited with both a caspase-8 and a 
caspase-9 inhibitor, suggesting cross ac-
tivities between the initiator caspases.
Mast cells and endothelial 
cell apoptosis
Mast cell activation downregulates 
bcl-2 expression in cocultured 
endothelial cells
ECs were isolated from the vasculature 
of rat myocardium and co-cultured for 
4 hours with either resting or activated 
rat serosal mast cells. In the absence of 
mast cells, as well as in the presence of 
resting mast cells (Study IV Figure 1, 
lanes 1 and 3), the ECs expressed signifi -
cant amounts of mRNA for two genes 
known to be involved in the regulation of 
apoptosis, the bcl-2 and the bax. When 
the mast cells were activated with the 
mast cell-specifi c noncytotoxic stimulant 
compound 48/80, an immediate release 
of ~80% of the stored histamine ensued, 
refl ecting signifi cant mast cell degranula-
tion. Within 30 minutes of the degranula-
tion, down-regulation (82%) of the mRNA 
expression of bcl-2 was observed in co-
cultured ECs (Study IV, Figure 1, lane 2, 
top panel). In contrast, the expression level 
of bax (Study IV, Figure 1 lane 2, mid-
dle panel) was not signifi cantly affected. 
These results show that mast cell degran-
ulation specifi cally down-regulated bcl-2 
expression in the co-cultured ECs.
To further identify the component(s) in 
the material released from the activated 
mast cells, i.e., mast cell releasate, which 
is (are) responsible for the observed 
down-regulation of bcl-2 mRNA expres-
sion, we separated the releasate into 
granule remnants and a granule remnant-
free supernatant by centrifugation at 
13,000g for 10 min. The major effect of 
bcl-2 down-regulation was found to reside 
in the sedimented granule remnant frac-
tion (Study IV, Figure 2 A, top panel). 
In addition, a smaller effect was also 
found to be present in the granule rem-
nant-free supernatant, whereas neither of 
the two fractions had a signifi cant effect 
on the mRNA expression of bax  (Study 
IV, Figure 2 A, middle panel). By using 
competitive RT-PCR, the granule rem-
nant-mediated down-regulation of the 
bcl-2 mRNA expression was found to be 
rapid, being already maximal (10-fold) 
after incubation for 30 minutes (Study IV, 
Figure 2 B, top panel) and the inhibitory 
effect lasted for up to 8 hours. Further-
more, there were no signifi cant changes 
in the expression level of bax (Study IV, 
Figure 2 B, middle panel). To verify the 
results obtained with RT-PCR, we ana-
lyzed the protein levels of bcl-2 and bax 
with western blotting in ECs, which were 
treated with granule remnants. As shown 
by immunoblotting, incubation of the 
ECs for 4 hours in the presence of gran-
ule remnants (Study IV, Figure 3, upper 
panel) resulted in a signifi cant reduction 
in bcl-2 protein. No signifi cant change 
in the protein level of bax was observed 
even after a prolonged period (18 h) of 
granule remnant treatment (Study IV, 
Figure 3, lower panel). 
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Mast cell granule remnants induce 
changes in bcl-2 and cytochrome c 
localisation in endothelial cells
Both the concentration and the localiza-
tion of bcl-2 and bax in mitochondria 
are important for the integrity of the 
mitochondria. Since changes in these two 
parameters are associated with mitochon-
drial leakage and onset of apoptosis, we 
analyzed their subcellular localization 
by immunocytochemistry. Untreated 
ECs exhibited a strong punctate immu-
nostaining of bcl-2 in their cytoplasm 
(Study IV, Figure 4, Panel A), compatible 
with the typical localization of bcl-2 to 
mitochondria. In addition, the cell nuclei 
also stained strongly for bcl-2. However, 
treatment of ECs with mast cell granule 
remnants resulted in extensive loss of the 
observed punctate immunostaining for bcl-
2 (Study IV, Figure 4, Panel B), refl ecting 
a decreased bcl-2 content in the mito-
chondria. The staining pattern for bax 
was found to be similar to that for bcl-2 
(Study IV, Figure 4, Panel C), indicating 
co-localization of the two apoptosis-
related bcl-2 family members. How-
ever, in contrast to bcl-2, bax appeared 
to remain localized to the mitochondria 
even after treatment with granule rem-
nants (Study IV, Figure 4, Panel D). 
Furthermore, untreated ECs also showed 
a positive punctate immunostaining 
for cytochrome c in their mitochondria 
(Study IV, Figure 4, Panel E), whereas 
the granule remnant-treatment resulted in 
a more diffuse staining of the cytoplasm 
(Study IV, Figure 4, Panel F). This result 
suggests that, in the presence of mast cell 
granule remnants, cytochrome c, a known 
initiator of caspase activation if present in 
the cytoplasm, was released from mito-
chondria into the cytoplasm of ECs. 
To further verify the translocation of 
cytochrome c from mitochondria to the 
cytoplasm, we subjected ECs to subcellu-
lar fractionation and analyzed the level of 
cytochrome c in the two specifi c sub-
fractions. The results of this experiment 
confi rmed that treating ECs with mast 
cell granules resulted in a translocation 
of cytochrome c from the mitochondria 
into the cytoplasm (Study IV, Figure 5), 
indicating a role for mitochondria leakage 
and cytochrome c release in the onset of 
mast cell-mediated EC apoptosis. 
Mast cell granule remnants induce 
endothelial cell apoptosis 
The apoptotic manifestation of the mast 
cell-mediated down-regulation of bcl-2 
expression was further verifi ed by 
propidium iodide- (PI), Hoechst 33342-, 
and Annexin-V-FLUOS staining, and 
fl ow cytometric analysis of ECs treated 
with mast cell-derived granule remnants. 
PI- and Hoechst 33342-staining of gran-
ule remnant-treated ECs showed signs 
of nuclear fragmentation, chromatin 
condensation, and blebbing typical for 
apoptotic cells (Study IV, Figure 6). An-
nexin-V-FLUOS staining further showed 
the presence of phosphatidyl serine on the 
surface of the treated ECs. Furthermore, 
by analyzing the granule remnant-treated 
ECs with fl ow cytometry, we could 
detect and quantitate a subgenomic DNA 
peak consistent with the presence of a 
cell population with apoptotic features. 
In addition, agarose gel electrophoresis 
of DNA isolated from granule remnant-
treated ECs showed a ladder of DNA 
fragments (~180 base pair increments) 
typical for apoptotic cells. In a parallel 
experiment, we excluded the presence of 
signifi cant necrosis by demonstrating that 
the culture media were devoid of lactate 
dehydrogenase (unpublished data).
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Mast cell-mediated endothelial 
apoptosis involves TNF-α 
To further defi ne the compound(s) 
responsible for the observed proapoptotic 
effects, we incubated ECs separately with 
three granule remnant components that 
are capable of inducing apoptosis, i.e., 
chymase, TGF-β, and TNF-α. We found 
that the mRNA expression of bcl-2 was 
signifi cantly down-regulated (60%) in the 
presence of TNF-α, suggesting that TNF-α
present in the mast cell granule remnants 
is involved in the observed effect (Study 
IV, Figure 7 A). Finally, to directly 
demonstrate that TNF-α is involved in 
granule remnant-mediated EC apoptosis, 
we incubated ECs with granule remnants 
in the presence of a TNF-α−neutralizing 
antibody. We found that in the presence 
of a TNF-α−neutralizing antibody, the 
granule remnant-induced EC apoptosis 
was partially inhibited (Study IV, Figure 
7 B).
Mast cell chymase inhibits 
smooth muscle cell growth 
and collagen expression
Mast cell chymase inhibits smooth 
muscle cell proliferation by block-
ing the G0/G1 → S transition 
To study the effect of chymase on SMC 
growth, we incubated growth-arrested 
SMCs with increasing concentrations of 
chymase and measured incorporation of 
[3H]thymidine after adding FCS to release 
cells from growth arrest. Incorporation of 
[3H]thymidine by growth-arrested SMCs 
was strongly inhibited in the presence 
of increasing amounts of chymase ac-
tivity (Study II, Figure 1 A). In addi-
tion, counting the cells at the end of the 
incubation revealed a dose-dependent 
decrease in the cell number (Study II, 
Figure 1 B). When growth-arrested 
SMCs were preincubated with mast cell 
chymase (20 BTEE units/mL) for 16 
hours, we observed a small reduction in 
cell number (Study II, Figure 1 D, 0 time 
point) which was due to chymase-medi-
ated apoptosis and disruption of cell-
matrix interactions with ensuing loss of 
adhering SMCs. Interestingly, when FCS 
was added to the incubation medium to 
inhibit chymase activity and to stimulate 
SMC proliferation, the rate of incorpora-
tion of [3H]thymidine by the SMCs was 
found to be signifi cantly reduced (Study 
II, Figure 1 C). The chymase-mediated 
growth-inhibitory effect lasted for up to 
72 hours, after which there was a rapid 
increase in [3H]thymidine incorporation 
to a level comparable to that of untreated 
cells. A similar effect was observed in 
the number of SMCs (Study II, Figure 
1 D). In a parallel experiment, we found 
only low percentages of apoptotic cells 
(analyzed by fl ow cytometry) during the 
exponential growth phase: about 2% in 
the chymase-treated SMC monolayer and 
0.4% in the untreated cells. Moreover, 
only a few trypan blue-positive cells were 
observed in either the chymase-treated 
or the untreated SMC monolayers. By 
using fl ow cytometric analysis, we found 
that the proportion of SMCs in the G
0
/G
1
phase was signifi cantly higher in the 
presence of chymase (54.6±2.5% versus 
47.3±0.9% for no treatment). In addition, 
the proportion of cells in the S phase was 
signifi cantly lower in the presence of 
chymase (32.1±3.0% versus 38.0±0.7% 
for no treatment), suggesting inhibition or 
delay of the G
0
/G
1
→ S transition in the 
chymase-treated SMCs.
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Anti-TGF-β neutralizing antibody 
partially blocks the inhibitory effect 
of preconditioned medium derived 
from chymase-treated smooth 
muscle cells
Because SMCs are known to produce and 
secrete TGF-β1 avidly and to respond to it 
by changing their rates of growth (Bobik
et al. 1999), we tested whether TGF-β1 
was involved in the observed chymase-
mediated inhibition of the growth. In 
the absence of anti-TGF-β neutralizing 
antibodies the preconditioned medium 
induced a 50% decrease in the rate of 
[3H]thymidine incorporation and in the 
cell number (Study II, Figure 2). In the 
presence of increasing concentrations of 
of anti-TGF-β neutralizing antibody, the 
rate of [3H]thymidine incorporation and 
cell number correspondingly increased, 
suggesting that TGF-β1 was responsible 
for the chymase-mediated inhibition of 
SMC growth. Addition of increasing 
concentrations of an anti-TGF-β antibody 
that recognizes active form of TGF-β 
to control SMCs did not increase their 
growth rate (unpublished data), indicating 
that the observed effect was due to the 
presence of active TGF-β1 in the precon-
ditioned medium. Furthermore, similar 
results were obtained with equivalent 
amounts of recombinant human TGF-β1. 
(Study II, Figure 2 C and D)  Interest-
ingly, inhibition of chymase activity in 
the preconditioned medium completely 
abolished the observed effects on DNA 
synthesis and cell growth in the treated 
SMCs (Study II, Figure 2 C and D).
Mast cell chymase releases active 
TGF-β1 from extracellular matrix of 
smooth muscle cells
To verify that rat aortic SMCs produce 
TGF-β1, we analyzed SMC monolayers 
by immunocytochemistry. SMCs were 
found to stain positively with a polyclonal 
antibody that recognizes both active and 
latent forms of TGF-β1 (Study II, Figure 
3 A). To separate intra- and extracellu-
lar TGF-β1, SMCs were cultured for 48 
hours, after which the cells were gently 
removed with 0.5% sodium deoxycholate. 
The remaining SMC-derived ECM also 
stained positively for TGF-β1.
As a further test of whether mast cell 
chymase could release and activate the 
TGF-β1 secreted by rat aortic SMCs, 
the cell monolayers were incubated with 
increasing amounts of chymase, and the 
concentration of TGF-β1 in the culture 
medium was detected by immunoblotting. 
The amount of active TGF-β1 (25 kDa) in 
the culture medium gradually increased in 
the presence of increasing concentrations 
of chymase. (Study II, Figure 3 B) By 
performing an ELISA assay with TGF-β1 
type II serine/threonine kinase receptor 
(TβRII) as capture, we found that chy-
mase signifi cantly increased the amounts 
of biologically active TGF-β1 released 
from the SMC monolayer (282±85 versus 
653±77 pg/106 cells) and from the SMC-
derived ECM (0 versus 140±28 pg/106
cells). Futhermore, the expression of 
PAI-1, an indicator of active TGF-β1, 
was signifi cantly induced (4.6 fold) in the 
presence of chymase (Study II, Fig-
ure 4A). No effect was observed in the 
expression of TβRI or TβRII. In contrast, 
in the chymase-treated SMCs, the ratio 
(target/competitor) of the specifi c TGF-β1 
signal was decreased (2.4 fold) (Study II, 
Figure 4B).
Mast cell chymase inhibits the ex-
pression of collagen type I and type 
III in a TGF-β-independent manner
Physiologically active TGF-β1 is known 
to induce collagen expression in SMCs in 
vitro (Amento et al. 1991). To test whether 
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mast cell chymase can induce collagen 
synthesis by SMCs through its activa-
tion of ECM-bound latent TGF-β1, the 
expression of mRNA of collagen types I 
and III, the predominant forms of col-
lagen in atherosclerotic lesions (Murata
et al. 1986), were detected by competi-
tive RT-PCR. Surprisingly, incubation of 
SMCs with chymase resulted in reduced 
mRNA expression of collagen type I (69 
%) and collagen type III (79 %) (Study 
II, Figure 5 A). Furthermore, addition of 
an anti-TGF-β neutralizing antibody to 
chymase-containing culture medium did 
not block the inhibitory effect of chymase 
on collagen expression in SMCs (Study 
II, Figure 5 B). These results suggest 
that the observed chymase-mediated 
inhibition of collagen mRNA expression 
had occurred independently of chymase-
mediated TGF-β1 activation. Indeed, the 
preconditioned medium, which was found 
to contain about 2 ng/mL of active TGF-
β1, had no effect on the collagen expres-
sion in the SMCs. However, when SMCs 
were treated with high concentrations of 
rhTGF-β1 (200 ng/mL), the expression 
of collagen type I was increased (2-fold), 
as has also been reported earlier (Amento
et al. 1991). Taken together, the above 
results are compatible with the notion that 
the chymase-induced decrease in SMC 
collagen expression did not depend on the 
presence of active TGF-β1. Furthermore, 
incubation of human coronary arterial 
SMCs with recombinant human chymase 
for 48 hours resulted in reduced expres-
sion of collagen I (74 %) and collagen III 
(23 %) in the treated human SMCs (Study 
II, Figure 5 C).
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Erosion or rupture of an atherosclerotic plaque with ensuing thrombosis is the 
cause of majority of all coronary events 
(Falk 1992; Lee et al. 1997). Infl amma-
tory cells, such as macrophages, T-cells 
and mast cells, being able to induce ECM 
degradation, loss of endothelium, inhibi-
tion of collagen production, and induction 
of cell death, may contribute to plaque 
disruption (Libby 2002). Increased num-
bers of mast cells have been observed at 
sites of plaque erosion or rupture in pa-
tients that have died of acute myocardial 
infarction (Kovanen et al. 1995), raising 
the hypothesis that mast cells could be 
involved in plaque destabilization. In 
order to test this hypothesis, we inves-
tigated the effects of mast cell-derived 
products on the growth, collagen synthe-
sis, and death of intimal SMCs and ECs 
in vitro.
Mechanism of chymase-induced 
smooth muscle cell apoptosis
The present study showed that activated 
rat serosal mast cells induce apoptosis of 
rat aortic SMCs and identifi ed chymase, 
a neutral serine protease secreted by 
the activated mast cells, as the active 
proapoptotic component. In addition, 
recombinant human chymase was found 
to be capable of inducing signifi cant 
apoptosis in cultured human coronary 
artery SMCs, indicating that the obser-
vation is not restricted to rodents, but is 
also potentially relevant in humans. The 
chymase-mediated apoptotic effect was 
completely dependent on the proteolytic 
activity, since inhibition of chymase with 
a trypsin inhibitor (TRINH) fully abol-
ished the induction of SMC apoptosis. Also, 
serum, which contains natural protease 
inhibitors, notably members of the serpin 
superfamily (Travis J et al. 1983) com-
pletely blocked the proteolytic activity of 
purifi ed chymase, and thus, prevented it 
from inducing apoptotic death of SMCs. 
However, chymase may be unique in that, 
after being secreted into the extracellular 
fl uid, it remains bound to the heparin PG 
matrix of the granule remnants and retains 
a part of its activity even in the presence 
of natural protease inhibitors, such as 
α
1
-antitrypsin, α
2
-macroglobulin, and α
1
-
antichymotrypsin (Lindstedt et al. 2001a). 
To mimick the conditions present in the 
extracellular fl uid of tissues, we have 
tested several neutral proteases for their 
ability to induce apoptosis in the presence 
of serum. Among the proteases tested, 
only heparin PG-bound chymase retained 
a part (~19 %) of its proteolytic activity 
in the presence of natural protease in-
hibitors (10% FCS), and was capable of 
inducing apoptosis. Thus, in comparison 
to other neutral proteases, mast cell-
derived granule remnant-bound chymase 
may possess the ability to degrade ECM 
components under in vivo conditions. 
The protease-induced apoptosis is not a 
unique phenomenon for mast cell chymase 
and SMCs, as several other neutral pro-
teases have been shown to exert proap-
optotic effects upon various cell types. 
The neutrophil serine proteases, elastase 
and proteinase 3, induce apoptosis in ECs 
(Yang et al. 1996), α-chymotrypsin and 
trypsin induce apoptosis in neutrophils 
(Trevani et al. 1996), and rat mast cell 
chymase induce apoptosis in cardio-
myocytes (Hara et al. 1999). Moreover, 
granzymes, serine proteases expressed 
exclusively by cytotoxic T lymphocytes 
and natural killer cells, are able to enter 
the target cells via perforin-mediated 
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endocytosis and trigger apoptosis by 
directly activating caspases (Trapani 
2001). Although granzymes, in their 
cleavage specifi city, show similarities 
with chymase (Kam et al. 2000), the 
granzyme-mediated apoptosis differs 
from the chymase-mediated apoptosis, as 
chymase exerts its proapoptotic activity 
in the extracellular space by affecting the 
ECM-cell interactions. 
In this study, we have identifi ed the 
ECM component fi bronectin (FN) to be 
a highly susceptible target of chymase-
mediated proteolysis and a crucial trigger 
of mast cell-mediated SMC apoptosis 
(Study III). Moreover, addition of puri-
fi ed chymase-generated FN degradation 
products to SMCs in culture induced 
SMC apoptosis similar to that observed 
with chymase. We also observed that 
the FN degradation products induced 
similar outside-in tyrosine phosphoryla-
tion signaling in SMCs, as did chymase. 
In particular, the focal adhesion kinase 
(FAK), one of the key mediators of focal 
adhesions and ECM-cell interactions was 
rapidly degraded, i.e., inactivated, in the 
presence of chymase and/or FN degrada-
tion products, leading to dephosphoryla-
tion of Akt, a downstream mediator of the 
FAK-dependent survival signaling cas-
cade. Moreover, chymase-induced SMC 
apoptosis could be inhibited by sodium 
orthovanadate, an inhibitor of tyrosine 
phosphatases, showing that changes in 
the stage of phosphorylation is critical in 
chymase-induced apoptosis.
The ECM exerts profound control over 
cells, regulating their proliferation, dif-
ferentiation and apoptosis. These effects 
are primarily mediated by the integrins, 
which regulate the activities of various 
cytoplasmic kinases, growth factor recep-
tors, and ion channels (Giancotti et al.
1999). The major FN-binding integrin, 
α5β1, has also been shown to mediate cell 
survival through outside-in signaling by 
activating protein tyrosine kinases, nota-
bly the FAK (Frisch et al. 1996; O’Brien
et al. 1996; Matter et al. 1998). Interest-
ingly, chymase and chymase-generated 
FN degradation products, when added to 
fresh cultures of SMCs, induced rapid 
degradation of FAK, suggesting that chy-
mase interferes with the FN-α5β1 integrin 
signaling pathway in the SMCs. 
In several cell types, including ECs 
(Scatena et al. 1998; Weaver et al. 2002) 
and neutrophils (Kilpatrick et al. 2002), 
integrin-mediated cell survival signaling 
has been shown to involve the activation 
of nuclear factor κB (NFκB). NFκB regu-
lates numerous genes involved in inter- 
and intracellular signaling, cellular stress 
responses, cell growth, differentiation, 
and survival (Gerondakis et al. 1999; 
Pahl 1999). Chymase treatment reduced 
the total amount of NFκB and abolished 
the translocation of active NFκB (p65) to 
the nucleus (Study V). A loss of NFκB-
mediated transactivation resulted in a 
downregulation of bcl-2 mRNA, fol-
lowed by reduced amounts of bcl-2 in the 
mitochondria. This is in accordance with 
the idea that NFκB is responsible for the 
expression of antiapoptotic molecules, 
such as bcl-2. These results suggest that 
chymase is able to interfere with the 
NFκB-mediated cell survival signaling 
system in SMCs.
Previously, two separate anti-apoptotic 
pathways associated with FN-integrin 
interactions and FAK-mediated down-
stream signaling have been demonstrated. 
Firstly, after serum withdrawal, FN has 
been shown to promote survival signals 
in fi broblasts and ECs by suppressing 
p53-mediated apoptosis through the FAK, 
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Ras/rac1/Pak1/MAPK kinase 4 (MKK4), 
and c-Jun NH2-terminal kinase (JNK) 
pathways (Almeida et al. 2000). Sec-
ondly, binding of the α5β1 integrin to FN 
in CHO cells upregulates the expression 
of anti-apoptotic genes, such as bcl-2, 
through an FAK-SHC-Ras-phosphati-
dylinositol 3´-kinase (PI3-kinase)-Akt 
pathway (Matter et al. 2001). Our present 
results show similarities with the latter 
pathway, in that chymase is able to dis-
rupt focal adhesion-dependent NFκB-me-
diated survival signaling (Fig 7).
The fi nal execution of the apoptotic 
process, i.e. the point of no return, is 
the activation of caspases. Treatment 
of SMCs with chymase induced activa-
tion of the initiator caspases -8 and -9, 
followed by activation of the executor 
caspases-3. Although, our initial results 
indicated that caspase-8 was the major 
pathway in chymase-mediated SMC 
apoptosis (Study I), our latter results have 
suggested an additional role for caspase-9 
in this process. Thus, in contrast to previ-
ous data (Budihardjo et al. 1999), clearly 
distinguishing between caspase-8, being 
the initiator of death receptor (extrinsic) 
pathway, and caspase-9, being the initia-
tor of the mitochondrial (intrinsic) path-
way of apoptosis, an increasing amount 
of studies, including our own, suggest a 
close interplay between the two cascades 
(Lassus et al. 2002). For instance, the 
Figure 7. Proposed mechanisms of mast cell-induced apoptosis
A schematic model illustrating the proposed mechanisms of mast cell induced apoptosis in SMCs and ECs. 
In SMCs, mast cell chymase degrades FN, disturbing the FN-α5β1 integrin interaction with subsequent 
degradation of FAK and loss of focal adhesions. As a consequence, Akt is dephosphorylated and NFκB is 
degraded, leading to downregulation of antiapoptotic bcl-2. In ECs, TNF-α released from activated mast 
cells downregulates bcl-2, leading to cytochrome c release and apoptosis. 
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mitochondrial pathway is used as an 
amplifi cation loop for the death receptor 
pathway (Li et al. 1998). Thus, the initia-
tor caspases may interact and amplify 
each other in the process of activating 
the executor caspases. Moreover, cas-
pase-2 has recently emerged as the most 
proximal caspase activated in cell stress 
signaling, and is able to activate both 
intrinsic and extrinsic apoptotic path-
ways (Schweizer et al. 2003; Troy et al.
2003). Presently, we do not know whether 
caspase-2 is involved in chymase-induced 
SMC apoptosis. Recent data, showing that 
caspase-8 may be activated by unligated 
integrins (Stupack et al. 2001) further 
suggest that there may also be additional 
pathways capable of triggering activation 
of apoptosis. Our present study, show-
ing disruption of focal adhesions, and 
hence, creation of unligated integrins, 
may involve the described mechanism of 
integrin-mediated caspase-8 activation.
Interestingly, cells seem to differ in 
their susceptibility to undergo protease-
induced apoptosis, as peripheral blood 
monocytes, lymphocytes, several hu-
man leukemic cell lines (THP-1, HL-60, 
K562), murine L929 fi broblasts, mouse 
peritoneal macrophages (Trevani et al.
1996) and myocardial fi broblasts (Hara et 
al. 1999) fail to undergo apoptosis after 
treatment with proteases. Many of these 
cell types (monocytes, lymphocytes and 
leukemic cell lines) grow in suspension 
and, consequently, do not depend on an-
choring to ECM for their survival, partly 
explaining their resistance to protease-
induced apoptosis. In contrast, fi broblasts 
and macrophages typically adhere to vari-
ous components of the ECM. The mecha-
nisms of these cells against protease-
induced apoptosis remain to be clari-
fi ed. Importantly, the mast cell-mediated 
proapoptotic effect seems to be a purely 
paracrine phenomenon, since activated 
mast cells themselves survive the process 
of degranulation by overexpressing the 
prosurvival bcl-2 homologue A1 (Karsan
et al. 1996).
Taken together, the present fi ndings sug-
gest an additional mechanism by which 
apoptosis of SMCs might be triggered in 
atherosclerotic lesions, namely, the action 
of chymase secreted by activated mast cells.
Mast cell -induced endothelial cell 
apoptosis 
Activated mast cells can also induce EC 
apoptosis by a mechanism involving 
rapid down-regulation of bcl-2 expression 
followed by the release of cytochrome 
c from the mitochondrial compartment 
(Study IV). The mast cell-mediated 
apoptotic effect was found to depend on 
mast cell stimulation and degranulation 
and to be present in the granule remnants, 
and, to a lesser degree, also in the granule 
remnant–free supernatant. Furthermore, 
the observed apoptotic effect was partially 
inhibited with a TNF-α neutralizing anti-
body, revealing involvement of TNF-α in 
this process. TNF-α has previously been 
shown to induce apoptosis in ECs by a 
mechanism involving down-regulation of 
the antiapoptotic molecule bcl-2 (Rossig
et al. 2000). 
Both the granule remnants and the granule 
remnant-free supernatant were capable of 
down-regulating bcl-2 mRNA expression 
in ECs, suggesting that mast cells may 
exert both short-range (granule remnant-
bound TNF-α) and long-range (soluble 
TNF-α) paracrine TNF-α-mediated 
effects. Whether there are other function-
al differences between the two fractions, 
such as differences in terms of TNF-α
presentation, is presently not known. In 
addition to the preformed TNF-α released 
upon degranulation, stimulated mast cells 
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have also been shown to secrete newly 
synthesized TNF-α (Gordon et al. 1991), 
a process that occurs more slowly but 
may enhance the initial response obtained 
with the rapidly secreted preformed TNF-α.
 Thus, our present results suggest that 
stimulated and degranulated mast cells, as 
a source of preformed granule remnant-
bound and soluble TNF-α, as well as newly 
synthesized soluble TNF-α, may have both 
acute and sustained effects on ECs. 
Cultured ECs are normally highly resist-
ant to apoptosis (Pohlman et al. 1989; 
Bach et al. 1997) and concomitant inhibi-
tion of either RNA- or protein synthesis 
is needed to trigger the apoptotic mecha-
nisms induced by various factors, includ-
ing TNF-α (Pohlman et al. 1989). Thus, 
in the presence of TNF-α, ECs protect 
themselves by activating the NFκB-
transcription factor pathway, which 
induces several anti-infl ammatory and 
antiapoptotic pathways, including bcl-2
(Bach et al. 1997; de Moissac et al.
1999). Interestingly, in our study the 
observed down-regulation of the bcl-2 
mRNA expression level in the ECs was 
found to be more extensive with mast 
cell granule remnants than with purifi ed 
recombinant TNF-α. Thus, it is likely that 
the granule remnant−mediated apoptosis 
in the cultured ECs is primed and sup-
ported by additional proapoptotic com-
ponents present in the granule remnants, 
such as chymase (Hara et al. 1999). Like 
SMCs, also ECs require intact ECM 
components, notably vitronectin (VN) 
for their survival (Scatena et al. 1998). 
As chymase is known to degrade VN, in 
addition to FN (Mayr et al. 2001), it is 
possible that VN degradation is involved 
in EC apoptosis.
The mast cell mediated SMC and EC 
apoptosis share mechanistical similari-
ties, in that integrin mediated outside-in 
signaling is crucial for cell survival. 
However, mast cell mediated endothelial 
cell apoptosis seems to involve also the 
secretion of proapoptotic cytokines, such 
as TNF-α. 
Mast cells as proapoptotic cells
Owing to the strategic location of mast 
cells at the host-environment interface 
and their extremely potent repertoire of 
mediators, mast cells have been proposed 
an evolutionary role in primary host 
defense, i.e., in killing invading bacteria 
and parasites, as well as infected and 
damaged cells (Gallagher et al. 2003; 
Puxeddu et al. 2003). Since a “clean” 
process of apoptotic death, in contrast to 
“dirty” necrotic death, would be the most 
feasible and physiological mechanism of 
such host defense, one could reason that 
mast cell-mediated proapoptotic mecha-
nisms could exist as a part of the normal 
host defense. Indeed, our results demon-
strate that mast cells, by releasing chymase 
and TNF-α, are able to induce SMC and 
EC apoptosis in vitro. In accordance, mast 
cell- derived chymase has previously been 
reported to induce cardiomyocyte apopto-
sis (Hara et al. 1999). Moreover, a recent 
paper suggested that mast cells are able 
to trigger apoptosis of Jurkat T leukemia 
cells through caspase-3, -8 and –9 inde-
pendent mechanisms (Gallagher et al.
2003). Thus, mast cells appear to possess 
several independent proapoptotic mecha-
nisms, and these may be cell-specifi c. 
Prerequisites for mast cell- 
mediated apoptosis
All current reports on mast cell- mediated 
apoptosis derive from in vitro studies, 
with no in vivo confi rmation. Thus, the 
defi nite proof of the relevance of mast 
cell- mediated apoptosis in atheroscle-
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rosis awaits future studies. However, 
the prerequisites for mast cell- mediated 
apoptosis seem to be fulfi lled in athero-
mas. Thus, in order to exert their effects 
mast cells have to be present in athero-
sclerotic lesions, and futhermore, they 
need to become activated. Recent studies 
have demonstrated the presence of acti-
vated, degranulated mast cells in human 
coronary plaques (Kaartinen et al. 1994a; 
Laine et al. 1999). Mast cell activation is 
normally strictly regulated, and normal 
arteries show low level of mast cell acti-
vation (Kaartinen et al. 1994a). Infl am-
matory mechanisms, such as complement 
activation, could be involved in mast 
cell activation in atheromas (Laine et al.
2002). Indeed, in the ruptured coronary 
plaques activated mast cells were associ-
ated with other infl ammatory cells (Laine
et al. 1999). It is possible that under 
chronic pathological conditions, such as 
atherogenesis, the ongoing mast cell ac-
tivation may contribute to undesired and 
excessive tissue and cell destruction.
Another important question is whether 
the number of mast cells in atheromas is 
high enough to infl uence the neigboring 
cells. Interestingly, the mast cell to SMC 
ratio has been determined to be 1:5 at 
the immediate site of erosion and rupture 
(Kovanen et al. 1995), which corresponds 
to the cell numbers used in our in vitro 
studies. Moreover, the concentration of 
chymase has been estimated to be 0.6 
µg/mL in the intimal fl uid of such vulner-
able areas (Lindstedt et al. 2001a), which 
is equivalent to approximately 6 BTEE 
units/mL, a concentration capable of 
inducing apoptosis in vitro. 
Mast cells inhibit smooth muscle 
cell growth and collagen expression
In addition to SMC and EC apoptosis, the 
plaque stability is affected by the rate of 
SMC proliferation and collagen synthesis. 
In the present study, we have described 
a novel mast cell chymase-dependent, 
TGF-β1-mediated paracrine growth-
inhibitory effect on SMCs. By adding 
purifi ed chymase to cultured rat aortic 
SMCs of synthetic phenotype we could 
obtain active soluble TGF-β1, which was 
capable of inhibiting their proliferation by 
blocking the G0/G1 →S cell cycle transi-
tion. Furthermore, chymase-mediated 
activation of TGF-β1 induced the expres-
sion of PAI-1, a sensitive bioindicator 
of TGF-β1-mediated cellular responses 
(Yang et al. 1999; D’Angelo et al. 2001), 
in the SMCs. Thus, we hypothesize that 
activated mast cells, by releasing chymase, 
may inhibit SMC growth through activa-
tion of TGF-β1 in tissues in which mast 
cells and SMCs coexist.
Interestingly, mast cell chymase, although 
releasing active TGF-β1 (a known col-
lagen-producing factor) from the ECM of 
the SMCs, has a net inhibitory effect on 
the expression of collagens of type I and 
type III in vascular SMCs. Indeed, under 
in vitro conditions, TGF-β1, depending 
on its concentration, was either with-
out effect or increased the expression 
of type I collagen by SMCs. Therefore, 
we infer that the inhibitory effect of 
chymase on collagen mRNA expression 
in the SMC cultures was not TGF-β1 
dependent. Since only active chymase 
exerted the inhibitory effect, the inhibi-
tory mechanism(s) is likely to involve 
proteolytic cleavage of some extracel-
lular factor(s) rather than mere binding 
of chymase to cell surface structures. 
As SMCs are the sole producers of the 
tensile components of the ECM (notably 
of collagen type I), a decrease in their 
numbers and synthesizing activity would 
lead to diminished production of these 
plaque-stabilizing molecules.
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Mast cells may destabilize 
coronary plaques
Taken together, our fi ndings raise the pos-
sibility that mast cells could participate 
in destabilization of coronary plaques by 
affecting the growth, function, and death 
of intimal SMCs and ECs. As shown in 
Figure 8, activated mast cells may induce 
SMC apoptosis by releasing chymase (A), 
induce EC apoptosis by releasing TNF-α
(B), inhibit collagen expression by SMCs 
(C), and inhibit SMC proliferation (D). 
When the present results are interpreted 
in the light of previous studies, showing 
that mast cells can inhibit proliferation 
of rat SMCs in vitro by releasing heparin 
PGs (Wang et al. 1999) and synthesize 
and activate matrix metalloproteinases 
(Di Girolamo et al. 2000), activated 
intimal mast cells appear to be a highly 
potential source of molecules capable of 
affecting plaque remodeling. However, 
the role of other infl ammatory cells in the 
process of plaque weakening and rupture 
should not be underscored. In this con-
text, the mast cell-mediated remodeling 
of the plaque, as described above, serves 
as a model for the overall role of infl am-
matory cells in the pathological process 
of plaque rupture. Future experiments 
will be necessary to determine the impor-
tance of the individual types of infl am-
matory cells in the onset, progression and 
execution of the pathological processes 
ultimately culminating in the rupture of 
an atherosclerotic plaque. 
Figure 8. A schematic model illustrating the various effects of activated intimal mast cells in the 
pathological process of weakening and rupture of an atherosclerotic plaque. 
The model depicts how activated mast cells in the shoulder region (the magnifi ed area) of an atheroscle-
rotic plaque may A.) induce SMC apoptosis, B.) induce EC apoptosis, C.) inhibit SMC-mediated collagen 
synthesis, and D.) inhibit SMC proliferation. 
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CONCLUSIONS
The aim of this study was to examine the possible role of mast cells in inducing apoptosis of SMCs and ECs. The following results were obtained in our in vitro
studies.
1. Chymase released from activated rat serosal mast cells is capable of inducing 
apoptosis of rat aortic SMCs in vitro. The proapoptotic effect requires proteolytic 
activity of chymase and is time- and dose- dependent. In addition to rat chymase, 
recombinant human chymase induces apoptosis of human coronary arterial SMCs 
in culture.
2. The mechanism of chymase-induced apotosis involves degradation of an ECM 
component, fi bronectin (FN). Commercial FN degraded by chymase induces SMC 
apoptosis in a similar magnitude, and with similar changes in outside-in signaling 
as chymase. FN degradation is followed by disruption of focal adhesions and 
degradation of focal adhesion kinase (FAK), one of the key mediators of integrin-
ECM interactions and cell survival. Loss of phosphorylated FAK (p-FAK) leads 
to a rapid dephosporylation of the p-FAK-dependent downstream mediator, Akt. 
Dephosphorylation appears to be critical for the chymase-induced apoptosis, as 
tyrosine phosphatase inhibitor sodium orthovanadate prevents the proapoptotic 
effect.
3. Following chymase treatment, the total amount of nuclear factor kappa B (NFκB) 
was reduced and the translocation of active NFκB (p65) to the nucleus was 
abolished. Loss of NFκB-mediated transactivation resulted in downregulation 
of bcl-2 mRNA expression. Due to the lack of antiapoptotic bcl-2, the apoptotic 
process was initiated and further executed by the activation of procaspases -3, -6, 
-8 and -9. 
4. Mast cell activation induces apoptosis of cocultured ECs. The effect is partially 
dependent on the presence of tumor necrosis factor-α and involves bcl-2 
downregulation and release of cytochrome c from mitochondria into the cytoplasm.
 5. Mast cell chymase inhibits SMC growth and collagen expression through both 
transforming growth factor-β dependent and independent mechanisms.
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